mRNA purification by tangential flow filtration

Tangential flow filtration with ammonium acetate and EDTA effectively purifies mRNA, addressing the issue of hydrolysis products and contaminants, resulting in high-purity mRNA suitable for pharmaceutical use.

JP2024167197APending Publication Date: 2024-12-03ETHRIS
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2024124252
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-02-11
Filing Date
2024-07-31
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing methods for purifying mRNA molecules are ineffective in removing hydrolysis products and contaminants, leading to impure mRNA solutions that can cause undesirable immune reactions and affect downstream applications.

Method used

A method involving tangential flow filtration (TFF) with multiple solution steps using ammonium acetate, water, and a chelating agent like EDTA to purify mRNA, effectively removing hydrolysis products and contaminants, ensuring high purity.

Benefits of technology

The method achieves high-purity mRNA solutions with minimal hydrolysis products and contaminants, suitable for downstream applications such as pharmaceutical compositions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167197000025
    Figure 2024167197000025
  • Figure 2024167197000026
    Figure 2024167197000026
  • Figure 2024167197000027
    Figure 2024167197000027
Patent Text Reader

Abstract

To provide a method of purifying mRNA molecules that are able to efficiently purify mRNA molecules on large scale, ensuring low levels of salts that can be problematic for downstream applications such as GSCN and using a system that can easily be automated.SOLUTION: The present disclosure provides a method of purifying mRNA molecules comprising (la) purifying precipitated mRNA molecules from a suspension comprising precipitated mRNA molecules, (lb) washing and dissolving the purified precipitated mRNA molecules, (lla) purifying the mRNA molecules using a solution comprising a chelating agent, followed by (lIb) washing the purified mRNA molecules, wherein steps (la) to (lIb) are performed using tangential flow filtration.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for the preparation of a method for the preparation of a precipitated mRNA molecule, comprising: (Ia) extracting the precipitated mRNA molecule from a suspension containing the precipitated mRNA molecule; (Ib) washing and dissolving the purified precipitated mRNA molecules. (IIa) purifying the mRNA molecules using a solution containing a chelating agent. and then (IIb) washing the purified mRNA molecules. A method for purifying an mRNA molecule, comprising the steps (Ia) to (IIb) of: The method is carried out using flow filtration. [Background technology]

[0002] Genetic information is stored in cells as deoxyribonucleic acid (DNA) and can be reproduced when needed. In some cases, a molecule can be transcribed into ribonucleic acid (RNA). Both DNA and RNA molecules can be A nucleic acid is a collection of nucleotides consisting of a nitrogenous base, a pentose sugar, and at least one phosphate group. There are various types of RNA, including mRNA molecules that carry the genetic information for protein synthesis. In eukaryotes, these mRNA molecules are produced from DNA as immature mRNAs. A molecule, followed by, for example, a 5' cap and a 3' polyadenosine (poly(A The mature mRNA molecule is then transported from the nucleus to the cytoplasm. The DNA sequence and the mature mRNA molecule are then transferred to the The amount, stability and translation efficiency primarily govern protein synthesis within the cell.

[0003] For example, to optimize the synthesis of a desired protein in a cell in a therapeutic context. In this paper, mRNA-based approaches represent a promising tool. The use of mRNA molecules includes: For protein translation, mRNA molecules must only be introduced into the cell's cytoplasm (Tavernier et al., 2011, J Control Release se, 150(3):238~247; Yamamoto et al., 2009, Eur J Pharm Biopharm, 71(3):484-489). In addition, plasmids, etc. In comparison to the use of individual DNA sequences contained in a suitable carrier, the use of mRNA molecules is It is less difficult and more efficient, and the plasmid or part of the plasmid is not integrated into the genome. There is no longer a very high risk that integration could alter chromosomal DNA. mRNA molecules, for example for therapeutic applications, are primarily generated by in vitro transcription. Such techniques involve linearization of the plasmid DNA itself or the cleavage of polynucleotides from the plasmid DNA. These are based on DNA templates generated by polymerase chain reaction (PCR). Both techniques are well established and can be easily scaled up. In either case, the mRNA molecules are prepared for downstream applications. Before it can be used, it must be refined.

[0004] Contaminants are present in most downstream applications, particularly in most downstream treatment applications. Purification of the synthesized mRNA molecules is important because various by-products can adversely affect their use in the field. The product is a desired mRNA, such as a component used and / or produced in an upstream process, such as mRNA synthesis. A molecules may be contaminated. However, short mRNA molecule fragments can be easily degraded by, for example, hydrolysis and abortive transcription. Hydrolysis of the mRNA molecule can occur through kinetic transcription. This hydrolysis can occur in the presence of a catalyst or enzyme, but can also occur spontaneously. Each mRNA molecule is then degraded to produce mRNA molecule fragments of variable length. Abortive transcription (e.g., Revyakin et al., 2006, Science ce, 314(5802):1139-1143), RNA polymerase , which binds to each promoter element in a DNA molecule for transcription and It unwinds the surrounding DNA duplex and initiates the synthesis of an mRNA molecule. In some cases, RNA polymerase does not escape the promoter region of the DNA, and the Sometimes the DNA remains motionless while some of it is translated. To accumulate, RNA polymerase binds to the DNA that stores the genetic information for transcription. Excrete the portion, releasing a synthetic RNA molecule of 1-15 nucleotides in length (e.g., Gol (See d.man et al., 2009, Science, 324(5929):927-928) For example, when a pharmaceutical composition containing such a short mRNA molecule fragment is administered, Further downstream applications, including the avoidance of undesirable immune responses, are identified. and purified, unfragmented, for further downstream therapeutic applications. It is highly desirable to have prepared mRNA molecules that have been purified.

[0005] Various techniques for purifying mRNA molecules, including precipitation and filtration and combinations thereof. For the purpose of removing undesired salts, nucleotides and proteins, For example, RNA precipitation-based techniques involve resuspending purified RNA molecules in a suitable buffer. This represents a cost-effective and convenient method to obtain turbid pellets. For this purpose, for example, guanidine thiocyanate (GSCN), ammonium acetate (NH4OA c) Using a variety of solutions, including ethanol, lithium chloride, and sodium acetate. (e.g., Walker and Lorsch, 2013, Methods (Reviewed by Enzymol. 530:337-343). is based on a mechanistic concept for purifying target molecules such as mRNA molecules. In the case of filtration, the feed, i.e., a solution or suspension containing target molecules such as mRNA molecules, is The turbidity passes through the filter membrane or across it. in the latter case it is called tangential flow filtration (TFF).

[0006] For example, WO2014 / 152966A1 and WO2015 / 164773A1 disclose To purify mRNA molecules using TFF while varying the volume of the solution and / or suspension, The present invention discloses a method for the synthesis of mRNA molecules containing, for example, urea, GSCN and / or potassium chloride. The mRNA molecules are purified by precipitating them using a ELISA kit, and the precipitate is washed multiple times. However, in either case, these methods produce unsuccessful mRNA molecules. and / or target mRNA taking into account short mRNA fragments such as hydrolysis products It has not been shown whether this allows for the purification of NA molecules.

[0007] WO2016 / 193206A1 describes a method for producing and purifying RNA, The RNA purification comprises at least one TFF step, preferably a phenol / chloroform does not include steps involving chloroform extraction and / or DNA and / or RNA precipitation, Further, the RNA molecules are preferably, for example, cation exchange and / or or ion exchange chromatography and / or reverse phase chromatography. As mentioned above, the above-mentioned publications have been published in the literature, which have been published in the literature. Target RNA molecules taking into account the hydrolysis products of NA molecules and / or mRNA molecules The purification of the compound is not disclosed.

[0008] WO2018 / 157133A1 discloses a method for the large-scale purification of mRNA molecules. The invention is particularly directed to a method for preparing a clean, homogenous composition of mRNA molecules using agitated centrifuges. As shown in the examples, The mRNA molecules were precipitated using GSCN, and the precipitate was prepared by mixing GSCN and ethanol. Interestingly, the m obtained by the claimed method The RNA molecule composition was compared to a composition containing mRNA molecules purified using TFF. TFF-based purification alone produces a solution that contains not only the target mRNA molecules but also residual enzymes. It has been shown that liquid was produced. [Prior art documents] [Patent documents]

[0009] [Patent Document 1] WO2014 / 152966A1 [Patent Document 2] WO2015 / 164773A1 [Patent Document 3] WO2016 / 193206A1 [Patent Document 4] WO2018 / 157133A1

[0010] [Non-Patent Document 1] Tavernier et al., 2011, J Control Release, 150(3):238-247; Yamamoto et al., 2009, Eur J Pharm Biopharm, 71(3):484-489 [Non-Patent Document 2] Revyakin et al., 2006, Science, 314(5802):1139-1143 [Non-Patent Document 3] Goldman et al., 2009, Science, 324(5929):927-928 [Non-Patent Document 4] Walker and Lorsch, 2013, Methods Enzymol, 530:337~343 Summary of the Invention [Problem to be solved by the invention]

[0011] Therefore, in particular failed mRNA molecules and the products of hydrolysis of mRNA molecules are taken into consideration. This allows efficient purification of mRNA molecules on a large scale, which has led to the development of novel GSCN and other Ensures low levels of salts that can be problematic in downstream applications and is easily automated Get an alternative solution that allows you to use a system that can be used at any time. There is still a need to have it done.

[0012] The present application provides, by the claimed embodiments, a purified mRNA This addresses the need to obtain A molecules in a high throughput manner. [Means for solving the problem]

[0013] In particular, the present invention relates to a method for preparing a suspension comprising: (Ia) using a first solution to precipitate mRNA molecules; (Ib) purifying the precipitated mRNA molecules from the solution using a second solution, The purified precipitated mRNA molecules obtained in step (Ia) are washed and dissolved. (IIa) using a third solution containing a chelating agent, purifying the mRNA molecules from the dissolved mRNA molecules obtained in step (a); (IIb) using the fourth solution to purify the purified chloroform obtained in step (IIa) and washing the mRNA molecule. The steps (Ia) to (IIb) are carried out using tangential flow filtration. do.

[0014] Surprisingly, the method according to the invention results in a high degree of purification of mRNA molecules, resulting in As examples, the term includes purified mRNA molecules, but does not include hydrolysis products and failed products of mRNA molecules. It has been found that this method results in a solution that is free or almost free of mRNA molecules. The application of the method prevents the formation of hydrolysis products, loss of mRNA molecules, which may be problematic for downstream applications. It was found that the lost mRNA molecules, proteins and salts were efficiently removed. By applying the method according to the invention, it is possible to obtain a product suitable for downstream applications, such as pharmaceutical applications. A solution containing purified mRNA molecules can be obtained. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] In the context of the present invention, the term "method for purifying" refers to the purification of said target A target molecule is extracted from a mixture, such as a solution or suspension, that contains components other than the target molecule and the target molecule. A method for obtaining a target molecule, comprising: - the concentration of the target molecule is different from the concentration of the target molecule in the mixture before carrying out the method The purification of a target molecule refers to a process in which the amount of the target molecule is increased or elevated in comparison to the amount of the target molecule. by removing or at least substantially removing components other than the target molecule, This can also be called molecular concentration.

[0016] In the context of the present invention, the target molecule is an mRNA molecule. The terms "mRNA" and "mRNA molecule" are used interchangeably. However, for example, A, C, G and / or U nucleotides, i.e., each nitrogenous base Single-stranded RNA consisting of nucleotides including adenine, guanine, cytosine, and uracil. It also refers to a molecular assembly. In addition, mRNA molecules are synthesized during translation. Thus, the mRNA to be purified contains one or more coding sequences that can be used as a template for The NA molecule is preferably a coding sequence, i.e., a sequence of amino acids that can be translated into a protein or the like. The coding sequence can be a sequence including a start codon and a stop codon. The sequence may be a sequence of the original or a partially or completely coding sequence derived from the natural sequence to be used. The sequence may be codon-optimized or may be an artificial sequence. It has been shown that there are codons that are preferentially used for a given amino acid by some species. For this reason, the expression of a protein is determined by the expression of the mRNA molecule corresponding to that protein. It refers to a technique used to maximize translation efficiency by increasing it. The RNA molecule may comprise a 5' untranslated region (UTR) and / or a 3' untranslated region, one or more sequences an internal ribosome entry site (IRES), one or more additional sequences to facilitate translation; and / or one or more modifications to modulate and / or extend the duration of action. Further features of the mRNA molecule are described in more detail below. Thus, the term "mRNA" is appropriate for the expression of an amino acid sequence or a protein. "A" is understood to mean any RNA molecule that can be translated into an amino acid sequence such as Thus, an "mRNA molecule" should be understood to mean a molecule that is a single molecule, and should be capable of expressing the same or similar properties and characteristics as that molecule. and / or exhibit an activity and therefore can be translated into an amino acid sequence such as a protein. It is intended to be understood as an mRNA molecule, the amino acid sequence of which is The nucleic acid sequences exhibit activities and / or properties that characterize the nucleic acid sequences.

[0017] As used herein, the term "amino acid sequence" refers to any type of amino acid sequence, i.e. That is, it consists of two or more amino acids, each of which is linked via a peptide bond. The term "encoded amino acid sequence" refers to any amino acid sequence of interest, including any amino acid sequence of interest. , at least 5 amino acids in length, more preferably at least 10 amino acids in length and even more preferably at least 50, 100, 20, 30, 40, 50, 60, 70, 80, 90, 10 ...100, 100, 100, 100, 100, 10 00 or 500 amino acids in length. Thus, the term "amino acid sequence" refers to a short Monoclonal peptides, oligopeptides, polypeptides, fusion proteins, proteins and known These fragments include parts of proteins, preferably functional parts thereof. The antigen may be, for example, a biologically active portion of a protein or may be effective in raising antibodies. The amino acid sequence may be an antigenic portion such as an epitope, which may be of any function. The amino acid sequence is not limiting and possible amino acid sequences are further detailed below.

[0018] In contrast, the components to be removed during the purification of the mRNA molecule, and thus the target molecule, Other components include, for example, mRNA molecules that are partially or completely degraded by hydrolysis. Decomposition by hydrolysis is a random process, and the resulting decomposition products are These are referred to in the specification as "hydrolysis products" or "hydrolysis products of mRNA molecules." It is at least one nucleotide shorter than the hydrolyzed mRNA molecule. Depending on the length of the mRNA molecule digested, the resulting hydrolysis products can be, for example, 10,000 nucleotides. Less than nucleotides, preferably less than 5,000 nucleotides, more preferably less than 500 nucleotides More preferably, less than 17 nucleotides, even more preferably less than 250 nucleotides. The length of the removed fragment may be less than 0 nucleotides, and most preferably less than 120 nucleotides. Another example of a target moiety is, for example, less than 50 nucleotides, preferably less than 25 nucleotides. More preferably, it is a failed mRNA molecule which may have a length of less than 15 nucleotides.

[0019] Additionally, components that may be removed during the purification of an mRNA molecule include, for example, in vitro Components used during in vitro synthesis of target molecules, such as transcription, and / or For the purpose of synthesis of ribozyme molecules and / or amplification of templates for transcription of mRNA molecules. In the case of in vitro transcription of mRNA molecules, Such components include, for example, proteins such as enzymes used for in vitro transcription; salts; ions such as sodium ions; nucleoside triphosphates; 5' caps and / or 5' caps Monophosphate, diphosphate, and / or triphosphate containing analogs; Abortive transcription products; hydrolysis products; 3-(N-morpholino)propanesulfonic acid ( buffers such as MOPS; and / or sharpeners such as ethylenediaminetetraacetic acid (EDTA); Contains thickening agents.

[0020] The method according to the invention is carried out by tangential flow filtration (TFF). The method comprises the steps of: a suspension or solution containing the mRNA molecules to be purified is applied to the surface of a filter membrane; The mRNA molecules preferably flow tangentially across the membrane from the membrane to the end. Therefore, TFF is a promising method for purifying mRNA molecules. By then, there is a possibility that the filter membrane may become clogged. Some filter cakes are no longer present, and as a result, the usable time of the filter membrane is reduced. You can make the interval longer. Therefore, the system for purifying a target molecule according to the present invention is a TFF system. TFF systems generally consist of a capsule, cassette and holder or hollow fiber module. a filter device such as a filter tube, a pump, tubing, a valve or clamp, a fluid reservoir, Optionally, a pressure gauge is provided (see FIG. 1). Such a TFF system has a high m Even high concentrations of RNA molecules do not block the pores of the filter membrane. The use of the TFF system allows for the purification of the mRNA fragments without the need for a continuous purification process. This is advantageous as it allows for high-throughput purification of the product.

[0021] Please note that the term "solution" generally refers to a homogeneous mixture of two or more substances. It applies in particular to the liquid state of matter, but gaseous and solid solutions are possible as well. In the text, the term "solution" is used in particular to refer to a "first solution", a "second solution" and a "second solution" according to the present invention. In the case of the "third solution" and the "fourth solution", water, a liquid that is preferably homogeneous and liquids, such as mixtures of a liquid, preferably with a dissolved salt.

[0022] According to the present invention, the precipitated mRNA molecules are extracted from a suspension containing the precipitated mRNA molecules. A method for purifying an mRNA molecule is provided, comprising the step of purifying (Ia). This is accomplished using a first solution. The suspension containing the precipitated mRNA molecules is then subjected to, for example, The precipitated mRNA can be obtained by cell lysis or in vitro transcription. The molecules include amino acid sequences, nucleoside triphosphates, and buffer components, including proteins and enzymes. and optionally cellular components such as 5' caps and 5' cap analogs. must be purified from the components of the in vitro transcription mixture. Cap analogs are, for example, sequences in which an mRNA molecule is transcribed in vitro and co-transcribed with a 5' capping agent. In the case where the suspension used to carry out step (Ia) is Thus, step (Ia) may be carried out by eluting cells from the precipitated mRNA molecules. It may be advantageous to remove components or components of the in vitro transcription mixture.

[0023] In some embodiments of the present invention, the first solution contains ammonium acetate (NH4OAc). Therefore, the precipitated mRNA molecules were obtained using a first solution containing NH4OAc. The first solution is purified from the suspension. Preferably, the range is 1 to 10, even more preferably, the range is 3 to 9, and most preferably, the range is 6 to 8. Thus, the precipitated mRNA molecules are eluted from the first elution solution containing NHOAc. The precipitated mRNA molecules are purified from the suspension using a solution ranging from 1 to 12, preferably Preferably, the range is 1 to 10, more preferably 3 to 9, and even more preferably 6 to 8. It has a pH range.

[0024] The method for purifying an mRNA molecule according to the present invention comprises the steps of: Washing and solubilizing the purified precipitated mRNA molecules obtained in Ia) (Ib). The second solution is capable of resuspending the mRNA molecules. Therefore, the mRNA molecule can be dissolved in any solution, e.g., water, in which it remains stable, i.e., does not hydrolyze. The step (Ib) is carried out in particular to remove the components of the first solution. In some embodiments of the present invention, it is advantageous to obtain a soluble mRNA molecule. The second solution is water.

[0025] The method of purifying mRNA molecules according to the present invention uses a third solution containing a chelating agent. and purifying the mRNA molecules from the dissolved mRNA molecules obtained in step (Ib). This further comprises the step (IIa) of extracting the mRNA from the solution containing the dissolved mRNA molecules. This is particularly advantageous for removing untreated mRNA molecules and hydrolysis products.

[0026] The term "chelating agent" refers to a molecule that chelates cations, particularly at pH and / or temperature, concentration of chelating agent and / or type of cation to be chelated. Depending on several factors, such as the amount of donor groups that can be attached to the central atom in a coordination compound, A chelator refers to a molecule that has, for example, dentates per molecule. number of donor groups and / or coordination sites on the cation to be chelated. For example, the chelating agent EDTA has six sites and Chelates divalent cations to form a 1:1 complex between the rating agent and the divalent cation. . Preferably, in the context of the present invention, the term "chelating agent" refers to, for example, a divalent mag. Divalent and / or non-divalent ions such as nesium ions and divalent calcium ions and / or trivalent iron ions refers to a chelating agent capable of complexing trivalent cations. Chelators with fewer than four coordination sites are particularly effective at complexing divalent and / or trivalent cations. In terms of the cation coordination site, it has a lower chelate than a chelator with four or more coordination sites. It has catalyzing activity.

[0027] The chelating agent according to the invention has at least four coordination sites on the cation to be chelated. and more preferably, the chelating agent has four coordination sites on the cation to be chelated. More preferably, the chelating agent is one or more of the chelating agents, also referred to as "strong chelating agents." More preferably, the chelating agent has at least four sites per molecule, , coordination sites on the cation to be chelated used in the pharmaceutical composition and / or formulation is more than four chelating agents, and even more preferably is EDTA. Chelating agents used in the present invention that have more than four coordination sites on the cation to be chelated For example, an antidot containing Na2EDTA solution (e.g., 2 g / 10 ml; see, for example, GPUPharma GmbH) and / or EDTA cal Antidot containing disodium citrate (e.g., 50 mg / ml, Amp. 10 ml; see, for example, Laboratoires SERB) or as an excipient, Used as an antiseptic (e.g., Phenhydan, Desitin Arzneimi ttel GmbH; or Soluvit N, Baxter; or Fluimucil , see Zambon GmbH).

[0028] Thus, in some embodiments of the present invention, the chelating agent is EDTA. Examples of suitable chelating agents are listed in Table 1, with EDTA being the most preferred chelating agent. be. [Table 1]

[0029] Strong chelating agents such as EDTA are particularly effective at absorbing divalent cations such as the magnesium cation. Magnesium cations are involved in the transcription of mRNA molecules, for example. It is present at high levels in cells and in vitro transcription mixtures because it is required by the enzyme The present inventors have used a strong chelating agent such as EDTA in step (IIa). By using this method, efficient removal of hydrolysis products and aborted mRNA molecules is achieved. This allows for a high degree of purification of mRNA molecules. Without being bound by theory, the cations mentioned above are It is possible to promote the formation of secondary and tertiary structures, especially magnesium cations. Removal of the divalent cations ensures that the mis-produced mRNA molecules and hydrolysis products are free of the divalent cations. In the presence of riboflavin, it may easily bind to the mRNA molecule to be purified, It has been hypothesized that this may be of particular relevance to the purification of the product. ) by removing divalent cations using a strong chelating agent such as EDTA This may lower the melting point and affect the secondary and / or tertiary structure of the mRNA molecule. is.

[0030] Therefore, failed mRNA molecules and hydrolysis products are removed as permeate. Therefore, step (IIa) is the step of removing the mis-produced mRNA molecules and hydrolysis products. It is particularly advantageous for removing objects.

[0031] According to the invention, the third solution contains a chelating agent, preferably a strong chelating agent as defined above. As noted above, the complex formation of a given chelating agent includes a chelating agent, most preferably EDTA. The complex building constant is affected by pH. Therefore, the complexing ability of chelating agents can be affected by pH. In terms of chelation of magnesium ions, a higher pH, such as pH 8 to 10, However, the complexing capacity of a given chelating agent and the m It is desirable to adjust the pH to optimize the trade-off between the stability of the RNA molecule and the pH. In this regard, strong chelating agents such as EDTA are preferred at pH levels between 1 and 10, preferably 6. It was observed that at a pH of ∼8, divalent cations in particular can be efficiently removed. Therefore, without being bound by theory, this may result in The melting point of the bound failed mRNA molecules and the hydrolysis products was increased by the addition of strong chelators such as EDTA. This can be reduced by activating agents, resulting in the formation of abortive mRNA molecules and hydrolysis. While removing the degradation products, the pH is simultaneously adjusted to a value that maintains the stability of the mRNA molecules to be purified. It is assumed that the Thus, in a preferred embodiment, p in a third solution containing a chelating agent is The H value is adjusted to the pH value at which each chelating agent has optimal chelating ability. Therefore, for example, at a pH of 1 to 10, preferably 6 to 8, a strong chelate such as EDTA is used. The use of a neutralizing agent is advantageous for efficient removal of divalent cations and therefore, This is advantageous for efficient removal of failed mRNA molecules and hydrolysis products. When one of the alternative chelating agents is used, the pH is adjusted to the appropriate level for the alternative chelating agent. ions, preferably divalent magnesium cations. The corresponding pH ranges are given in the above for the preferred chelating agents. It is shown in the table.

[0032] In some embodiments, the third solution has a molecular weight in the range of 1 to 10, preferably 3 to 9, more preferably Most have a pH in the range of 6 to 8.

[0033] The pH of the third solution can be achieved using a buffer. The pH ranges for each of these buffers are given in parentheses. -Hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol (Bis-Tris; pH range 5.8-7.2), N-(2-acetamido)iminodiacetic acid Acid (ADA; pH range 6.0-7.2), N-(2-acetamido)-2-aminoethane Sulfonic acid (ACES; pH range 6.1-7.5), 1,4-piperazinediethanesulfonate Polymorphic acid (PIPES; pH range 6.1-7.5), 2-hydroxy-3-morpholine-4- MOPSO; pH range 6.2-7.6), 1,3-bis(methylenedioxypropane-1-sulfonic acid (Tris(hydroxymethyl)methylamino)propane (BisTrispropane; pH range 6.3~9.5), N,N-bis(2-hydroxyethyl)-2-aminoethanesulfone Acid (BES; pH range 6.4–7.8), 3-(N-morpholino)propanesulfonic acid ( MOPS; pH range 6.5-7.9), 2-[[1,3-dihydroxy-2-(hydroxy Dimethyl)propan-2-yl]amino]ethanesulfonic acid (TES; pH range 6.8~ 8.2), 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfone Acid (HEPES; pH range 6.8-8.2), 3-(N,N-bis[2-hydroxyethyl Diphenylamino)-2-hydroxypropanesulfonic acid (DIPSO; pH range 7.0-8. 2) 4-(N-morpholino)butanesulfonic acid (MOBS; pH range 6.9-8.3) and 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]a Amino]-2-hydroxypropane-1-sulfonic acid (TAPSO; pH range 7.0-8. 2). Particularly preferred buffers have a preferred pH of 6 to 8, more preferably 6.5. MOPS has a pH of ~7.5.

[0034] In some embodiments, the third solution has a molecular weight in the range of 1 to 10, preferably 3 to 9, more preferably The pH of the solution is preferably in the range of 6 to 8, and contains a buffer, preferably MOPS.

[0035] In some embodiments of the invention, the third solution comprises a MOPS buffer, preferably In addition, the pH of the MOPS buffer should be adjusted before the addition of the chelating agent, preferably EDTA. and Thus, in some embodiments of the present invention, divalent cations, such as magnesium cations, are preferred. The third solution, preferably containing EDTA as a chelating agent to remove MOPS In some embodiments of the present invention, the MOP Prepare S buffer, and adjust the pH of the MOPS buffer to 1 to 10, preferably 6 to 8. After adjusting the pH, the third step is carried out by adding EDTA as a preferred chelating agent. A solution can be obtained. In some embodiments of the invention, the third solution is 40 mM MOPS and 10 mM EDT. A and has a pH of 6 to 8, preferably a pH of 6.5 to 7.5.

[0036] The method for purifying an mRNA molecule according to the present invention further comprises the steps of: The method further comprises the step (IIb) of washing the purified mRNA molecules obtained in a). The fourth solution is one in which the mRNA molecules remain stable, i.e., do not undergo hydrolysis. Step (IIb) may be carried out by using any solution, for example, sodium chloride. If the third solution contains sodium citrate or sodium citrate, or is water, It is advantageous to remove

[0037] As described above, the second and fourth solutions are those in which the mRNA molecules remain stable, i.e. That is, it may be any solution that does not hydrolyze. Such a fluid may be, for example, water, preferably Alternatively, the solution may be nuclease-free water or RNase-free water, such as water for injection (WFI water). Furthermore, in the case of the fourth solution, such a fluid may be, for example, HEPES-buffered glucose , sodium chloride and / or sodium citrate.

[0038] Thus, in some embodiments of the present invention, the fourth solution is water. In an embodiment, the second and fourth solutions are water. In some embodiments of the present invention, the fourth solution comprises sodium chloride and / or sodium citrate. Includes Umu.

[0039] In some embodiments of the invention, the second solution is water and / or the fourth solution is water. or containing sodium chloride and / or sodium citrate. Step (IIb) may be followed by further steps before further downstream processing or use. Purified mRNA molecules can be synthesized without introducing components that must be removed during It is advantageous to obtain a solution containing

[0040] In a preferred embodiment of the present invention, the second solution is water and the fourth solution is preferably Contains sodium chloride and / or sodium citrate with a pH of 4-5. Sodium citrate and / or sodium citrate are preferably used in pharmaceutical compositions containing purified mRNA molecules. Inclusion in the composition is highly advantageous, particularly in the context of therapy. This is a pharmaceutical composition in which sodium chloride and / or sodium citrate are frequently used. Therefore, from the viewpoint of later incorporating the obtained mRNA molecule into a pharmaceutical composition, Therefore, sodium chloride or chlorine, which is a preferred component of the pharmaceutical composition, is advantageous. Purifying the mRNA molecules by using a fourth solution containing sodium enoate. and the steps required to incorporate said mRNA molecule into a pharmaceutical composition. This enables time- and cost-effective integration with cloud-based applications.

[0041] If the fourth solution contains sodium chloride and / or sodium citrate, The pH is preferably 3 to 6, more preferably 3.5 to 5.5, and even more preferably 4 to The number is 5.

[0042] In a preferred embodiment of the process according to the invention, ethanol is used in said process. The first, second, third and / or fourth solutions are not included.

[0043] As mentioned above, it is surprising that the application of the method according to the invention allows the production of high-grade mRNA molecules. It has been found that purification can be achieved. The resulting solution contains purified mRNA molecules, but also hydrolysis products and failed mRNA molecules. More preferably, the percentage of mRNA molecules that are The rate is the rate at which all RNA molecules (mRNAs) in the solution obtained after step (IIb) are At least 80% of the mRNA molecules (mRNA molecules, hydrolysis products and abortive mRNA molecules) More preferably, it is at least 90%, and even more preferably, it is at least 95%. For example, gel electrophoresis, high performance liquid chromatography (HPLC) analysis, and other techniques well known to those skilled in the art. Alternatively, the concentration can be measured by capillary gel electrophoresis or Fl Electrophoretic analysis using capillary electrophoresis such as agment analyzer The latter method is illustrated in the examples below. This is explained in more detail by way of example in US Pat.

[0044] In some embodiments of the present invention, at least step (IIa), preferably step (IIb), Ia) to (IIb) are carried out at a temperature of 0° C. to 25° C., preferably at a temperature of 2° C. to 8° C. Thus, the process according to the invention, at least in the case of step (IIa), comprises: That is, a third solution containing a strong chelating agent, preferably EDTA, is used to perform the step In the case of purifying mRNA molecules from the dissolved mRNA molecules obtained in step (Ib), The reaction is preferably carried out at 0° C. to 25° C. As a result, the number of failed mRNA molecules and The hydrolysis product is reacted with the hydrolysis product of step (IIa) at a temperature between 0° C. and 25° C., preferably at a temperature between 2° C. and 8° C. ) is carried out. Particularly lower temperatures, such as temperatures between 2°C and 8°C, are The amount of degradation of mRNA molecules by water degradation increases stepwise at higher temperatures, especially at temperatures above 25°C. This is advantageous since it reduces the amount of decomposition observed compared to that observed when (IIa) is carried out. Therefore, in order to obtain large amounts of purified mRNA molecules, at least the method according to the present invention is Step (IIa) of the process, preferably at least steps (Ia) to (IIb), are carried out It is advantageous to carry out the reaction at a temperature between 2°C and 25°C, preferably between 2°C and 8°C.

[0045] In some embodiments of the invention, the precipitated mRNA molecules contained in the suspension are preferably The purified DNA according to the present invention is obtained by in vitro transcription. The mRNA molecule to be produced can be produced by any method known in the art. Preferably, the mRNA molecule is transcribed in vitro using a DNA template.

[0046] In vitro transcription requires a promoter, ribonucleotide triphosphates, a buffer system, and T7 RNA. A purified, linear or nonlinearized RNA polymerase containing a suitable RNA polymerase, such as RNA polymerase A. For example, such a purified linear DNA template can be used as an inducing It can be chemically synthesized in vitro, optionally followed by, for example, PCR-based Alternatively, the DNA template for transcription is generally It is obtained by cell lysis, purified and linearized, for example, using a site-specific restriction enzyme. Alternatively, it may be obtained from a DNA plasmid. In either case, the resulting line The DNA template sequence was amplified by A, C, G and U nucleotides using standard experimental protocols. It can be used for in vitro transcription of mRNA molecules in the presence of

[0047] In some embodiments of the present invention, the mRNA molecules to be purified include unmodified and / or modified nucleic acids. It is produced by in vitro transcription in the presence of leutidine. The mRNA molecule is linear or linearized by the use of unmodified and / or modified nucleotides. The nucleic acid sequence can be synthesized by in vitro transcription based on a DNA template prepared as described herein. The term "unmodified nucleotides" as used herein refers to the above A, C, G, T and In particular, in the case of in vitro transcription of mRNA molecules, The term "modified nucleotides" as used herein refers to A, C, G and U nucleotides. The term "nucleotide" refers to any naturally occurring or chemically synthesized A, C, G, T and U nucleotide. isomers of leutidine and any natural or chemically synthesized analogs, alternative or modified nucleotides. Modifications refer to nucleotides or isomers thereof that have, for example, chemical modifications or substituted residues. The nucleotides can have base modifications and / or sugar modifications. , can also have phosphate group modifications, e.g., directed to the 5' cap of an mRNA molecule. Modified nucleotides are nucleotides synthesized post-transcriptionally by covalent modification of nucleotides. Additionally, any suitable mixture of unmodified and modified nucleotides may also be used. A non-limiting number of examples of modified nucleotides can be found in the literature (e.g., Cantara et al. , Nucleic Acids Res, 2011, 39(Issue suppl_1 ):D195-D201; Helm and Alfonzo, Chem Biol, 2014 , 21(2):174-185; Carell et al., Angew Chem Int Ed. Engl, 2012, 51(29):7110-31) Some preferred modified nucleotides are based on each nucleoside residue: The following are mentioned as examples: 1-Methyladenosine, 2-Methylthio-N6-hydroxynorvalylcarbamoyladenosine Adenosine, 2-methyladenosine, 2'-O-ribosylphosphate adenosine, N6-methyl- N6-Threonylcarbamoyl adenosine, N6-Acetyl adenosine, N6-Glycinyl N6-isopentenyladenosine, N6-methyladenosine , N6-threonylcarbamoyl adenosine, N6,N6-dimethyl adenosine, N6- (cis-Hydroxyisopentenyl)adenosine, N6-Hydroxynorvalylcarba 1,2'-O-dimethyladenosine, N6,2'-O-dimethyladenosine adenosine, 2'-O-methyladenosine, N6,N6,2'-O-trimethyladenosine, 2-Methylthio-N6-(cis-hydroxyisopentenyl)adenosine, 2-Methyl Thio-N6-methyladenosine, 2-methylthio-N6-isopentenyladenosine, 2 -Methylthio-N6-threonylcarbamoyl adenosine, N6-2-methylthio-N6 -Threonylcarbamoyl adenosine, 2-methylthio-N6-(cis-hydroxyiso (sopentenyl) adenosine, 7-methyl adenosine, 2-methylthioadenosine, 2-methyl 2'-Amino-2'-deoxyadenosine, 2'-azido-2'-deoxyadenosine Oxyadenosine, 2'-fluoro-2'-deoxyadenosine, 2-aminopurine, 2 ,6-Diaminopurine, 7-Deazaadenosine, 7-Deaza-8-azaadenosine, 7- Deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2 ,6-Diaminopurine, 7-deaza-8-aza-2,6-diaminopurine; 2-thiothio cytidine, 3-methylcytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine Cytidine, 5-methylcytidine, 5-hydroxymethylcytidine, 5-hydroxycytidine Cytidine, Lysidine, N4-acetyl-2'-O-methylcytidine, 5-formyl-2'- O-methylcytidine, 5,2'-O-dimethylcytidine, 2-O-methylcytidine, N4 ,2'-O-Dimethylcytidine, N4,N4,2'-O-Trimethylcytidine, Isocytidine cytidine, pseudocytidine, pseudoisocytidine, 2-thiocytidine, 2'-methyl-2 '-Deoxycytidine, 2'-amino-2'-deoxycytidine, 2'-fluoro-2' -Deoxycytidine, 5-iodocytidine, 5-bromocytidine, 2'-azido-2'- Deoxycytidine, 2'-amino-2'-deoxycytidine, 2'-fluoro-2'-deoxycytidine Oxycytidine, 5-azacytidine, 3-methylcytidine, 1-methylpseudoisocytidine cytidine, pyrrolocytidine, pyrrolopseidoisocytidine, 2-thio-5-methylcytidine, 4-thiopseudoisocytidine, 4-thio-1-methylpseudoisocytidine, 4-thio -1-Methyl-1-deazapseudoisocytidine, 1-Methyl-1-deazapseudoisocytidine Cytidine, 2-methoxycytidine, 2-methoxy-5-methylcytidine, 4-methoxyprop Pseudoisocytidine, 4-Methoxy-1-Methylpseudoisocytidine, Zebularine, 5 -Azazebularine, 5-methylzebularine, 5-aza-2-thiozebularine, 2-thiozebularine 1-Methylguanosine, N2,7-dimethylguanosine, N2-methylguanosine Syn, 2'-O-ribosyl phosphate guanosine, 7-methylguanosine, hydroxylamine Tosine, 7-aminomethyl-7-deazaguanosine, 7-cyano-7-deazaguanosine , N2,N2-dimethylguanosine, N2,7,2'-O-trimethylguanosine, N2 ,2'-O-dimethylguanosine, 1,2'-O-dimethylguanosine, 2'-O-methyl Guanosine, N2,N2,2'-O-trimethylguanosine, N2,N2J-trimethyl Lguanosine, isoguanosine, 4-demethylguanosine, epoxyguanosine, incomplete Undermodified hydroxywybutosin, incompletely methylated Hydroxywybutosin, isowybutosin, peroxywybutosin, galactosyl que Osin, Mannosilk Eosin, Queosin, Archaeosin, Wybutosin, Methylwa Iosine, Wyosine, 7-aminocarboxypropyl demethyl wyosine, 7-amino Carboxypropyl wyosin, 7-aminocarboxypropyl wyosin methyl ester le, 7-deazaguanosine, 7-deaza-8-azaguanosine, 6-thioguanosine, 6 -Thio-7-deazaguanosine, 6-Thio-7-deaza-8-azaguanosine, 7-Methionine 6-thio-7-methylguanosine, 7-methylinosine, 6-methoxyguanosine Anosine, 1-methylguanosine, 8-oxoguanosine, 7-methyl-8-oxoguanosine Nosine, 1-methyl-6-thioguanosine, N2-methyl-6-thioguanosine, N2, N2-Dimethyl-6-thioguanosine, N1-Methylguanosine, 2'-Amino-3'- Deoxyguanosine, 2'-azido-2'-deoxyguanosine, 2'-fluoro-2' -Deoxyguanosine, 2-thiouridine, 3-(3-amino-3-carboxypropyl ) Uridine, 3-methyluridine, 4-thiouridine, 5-methyl-2-thiouridine, 5-Methylaminomethyluridine, 5-carboxymethyluridine, 5-carboxymethyluridine Aminomethyluridine, 5-hydroxyuridine, 5-methyluridine, 5-taurino Methyluridine, 5-carbamoylmethyluridine, 5-(carboxyhydroxymethyl ) Uridine methyl ester, dihydrouridine, 5-methyldihydrouridine, 5-methyl Aminomethyl-2-thiouridine, 5-(carboxyhydroxymethyl)uridine, 5 -(Carboxyhydroxymethyl)-2'-O-methyluridine methyl ester, 5-( Isopentenylaminomethyl)uridine, 5-(isopentenylaminomethyl)-2-thio Auridine, 3,2'-O-dimethyluridine, 5-carboxymethylaminomethyl-2 '-O-Methyluridine, 5-carbamoylhydroxymethyluridine, 5-carbamoyl 5-carbamoylmethyl-2'-O-methyluridine, 5-carbamoylmethyl-2-thiouridine, -Methoxycarbonylmethyl-2'-O-methyluridine, 5-(isopentenylamino methyl)-2'-O-methyluridine, 5,2'-O-dimethyluridine, 2'-O-methyl Thioluridine, 2'-O-methyl-2-thiouridine, 2-thio-2'-O-methyluridine Uridine 5-oxyacetic acid, 5-methoxycarbonylmethyluridine, uridine 5-oxy 5-Methoxyuridine, 5-Aminomethyl-2-thiouridine , 5-carboxymethylaminomethyl-2-thiouridine, 5-methylaminomethyl-2 -Selenouridine, 5-methoxycarbonylmethyl-2-thiouridine, 5-taurinome 1-methyl-3-(3-amino-3-carbazolidine, 2-thiouridine, pseudouridine, 1-Methylpseudouridine, 3-Methylpseudouridine Uridine, 2'-O-methylpseudouridine, 5-formyluridine, 5-aminomethyl 2-geranyluridine, 5-taurinomethyluridine, 5-iodouridine, 5-bromo romouridine, 2'-methyl-2'-deoxyuridine, 2'-amino-2'-deoxy Uridine, 2'-azido-2'-deoxyuridine, 2'-fluoro-2'-deoxyuridine Lysine, inosine, 1-methylinosine, 1,2'-O-dimethylinosine, 2'-O- Methylinosine, 5-azauridine, 2-thio-5-azauridine, 4-thiopseudododecane Lysine, 2-thiopseudouridine, 5-carboxymethyluridine, 1-carboxymethyluridine Tyrpseudouridine, 5-propynyluridine, 1-propynylpseudouridine, 1 -Taurinomethylpseudouridine, 5-taurinomethyl-2-thiouridine, 1-taurinomethyl- Linomethyl-4-thiouridine, 5-methyluridine, 1-methylpseudouridine, 4 -Thio-1-methylpseudouridine, 2-Thio-1-methylpseudouridine, 1-Me 2-thio-1-methyl-1-deazapseudouridine, 2-thio-1-methyl-1-deazapseudouridine dihydropseudouridine, 2-thiodihydrouridine, 2-thiodihydropseudouridine Uridine, 2-methoxyuridine, 2-methoxy-4-thiouridine, 4-methoxyps Idouridine, 4-methoxy-2-thiopseudouridine, 1,2'-O-dimethyladenylidene Inosine, 1,2'-O-dimethylguanosine, 1,2'-O-dimethylinosine, 2,8 -Dimethyladenosine, 2-Methylthiomethylenethio-N6-isopentenyladenosine , 2-geranylthiouridine, 2-lysidine, 2-methylthio cyclic N6-threonyl carbamide Bamoyl adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl) a Adenosine, 2-Methylthio-N6-hydroxynorvalylcarbamoyl adenosine, 2- Methylthio-N6-threonylcarbamoyl adenosine, 2-Selenouridine, 2-Thio -2'-O-methyluridine, 2'-O-methyladenosine, 2'-O-methylcytidine , 2'-O-methylguanosine, 2'-O-methylinosine, 2'-O-methylpseudo Uridine, 2'-O-methyluridine, 2'-O-methyluridine 5-hydroxyacetate methyl Ester, 2'-O-ribosyl adenosine phosphate, 2'-O-ribosyl guanosine Phosphate, 3,2'-O-dimethyluridine, 3-(3-amino-3-carboxylate 3-(3-amino-3-carboxypropyl)-5,6-dihydrouridine Pseudouridine, 5,2'-O-dimethylcytidine, 5,2'-O-dimethyluridine, 5-(Carboxyhydroxymethyl)-2'-O-methyluridine methyl ester, 55 -(Isopentenylaminomethyl)-2'-O-methyluridine, 5-aminomethyl-2'-O-methyluridine -Geranylthiouridine, 5-aminomethyl-2-selenouridine, 5-aminomethyluridine Lysine, 5-carbamoylmethyl-2'-O-methyluridine, 5-carboxyhydroxy Dimethyluridine, 5-carboxymethyl-2-thiouridine, 5-carboxymethyl Aminomethyl-2-geranylthiouridine, 5-carboxymethylaminomethyl-2-seleno Nouridine, 5-carboxymethylaminomethyl-2'-O-methyluridine, 5-cyano Nomethyluridine, 5-formyl-2'-O-methylcytidine, 5-methoxycarbonyl Methyl-2'-O-methyluridine, 5-methylaminomethyl-2-geranylthiouridine 7-aminocarboxypropyl demethylguanosine, 7-methylguanosine, 8-methylguanosine Chiladenosine, N2,2'-O-dimethylguanosine, N2,7,2'-O-trimethyl 2,7-Dimethylguanosine, N2,N2,2'-O-Trimethylguanosine N2,N2,7-trimethylguanosine, N2,N2,7-trimethylguanosine N4,2'-O-dimethylcytidine, N4,N4,2'-O-trimethylcytidine, N4,N4-Dimethylcytidine, N4-Acetyl-2'-O-Methylcytidine, N6,2 '-O-Dimethyladenosine, N6,N6,2'-O-Trimethyladenosine, N6-H Lumiladenosine, N6-hydroxymethyladenosine, agmatidine, 2-methylthio Cyclic N6-threonylcarbamoyl adenosine, glutamyl eosine, any nucleoside Guanosine added to the tide, guanylylated 5' end, hydroxy-N6-threo most preferably, pseudouridine, N1-methylpseudoimide Douridine, 2'-fluoro-2'-deoxycytidine, 5-iodocytidine, 5-methyl Lucitidine, 2-thiouridine, 5-iodouridine and / or 5-methyluridine.

[0048] Additionally, the term "modified nucleotide" refers to a nucleotide that contains an isotope, such as deuterium. The term "isotopes" refers to atoms that have the same number of protons but different numbers of neutrons. The term refers to elements that have different mass numbers and thus have different nuclei. Thus, for example, the isotopes of hydrogen are In addition, the mRNA molecule may contain, but is not limited to, deuterium, tritium, etc. Modified nucleotides may contain isotopes of other elements, including nitrogen and phosphorus. or may be replaced by another isotope of hydrogen or another isotope of oxygen, carbon, nitrogen or lithium. It may contain isotopes of 1,2-dinitrophenyl ether.

[0049] Therefore, the mRNA molecule to be purified must contain four nucleotide types: A, C, When produced by in vitro transcription in the presence of G and U nucleotides, the modified nucleotide The total number of nucleotide forms may be 0, 1, 2, 3 or 4. Thus, in some embodiments In some embodiments, at least one nucleotide of one nucleotide type, e.g., at least Every U nucleotide may be a modified nucleotide. At least one nucleotide belonging to a total of two nucleotide types, e.g., at least One U nucleotide and at least one C nucleotide are modified nucleotides. In some embodiments, at least one nucleotide belonging to a total of three nucleotide types may be present. nucleotide, e.g., at least one G nucleotide, at least one U nucleotide The C nucleotide and at least one C nucleotide may be a modified nucleotide. In an embodiment, at least one nucleotide of all four nucleotide types is modified. In all of these embodiments, each nucleotide type may be a modified nucleotide. One or more nucleotides may be modified per nucleotide type. The percentage of modified nucleotides was 0%, 2.5%, 5%, 7.5%, 10%, 15%, 20%, %, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70 %, 75%, 80%, 85%, 90% or 100%. In some embodiments, the total percentage of modified nucleotides in the mRNA molecule to be purified The rates are 0%, 2.5%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 3 5%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 8 5%, 90% or 100%.

[0050] The mRNA molecule to be purified contains, for example, 0.5 to 50%, preferably 5 to 10% U nucleotides. 50% of the C nucleotides and 5 to 50% of the C nucleotides are modified. The modified U nucleotide is preferably 5-iodouridine, and the modified C nucleotide is preferably 5-iodouridine. The amide is preferably 5-iodocytidine. In some embodiments, the mRNA molecule to be purified contains 15-25% U and 15-25% C nucleotides. 5-15% of the nucleotides are modified, and the modified U nucleotides are preferably 5-methyluridine, and the modified C nucleotide is preferably 5-iodocytidine. The present invention may be characterized in that it is In some embodiments, the mRNA molecule to be purified contains 30-50% U nucleotides and 10-20% of the C nucleotides are modified, and the modified U nucleotides are preferably is 5-iodouridine, and the modified C nucleotide is preferably 5-iodosin It may be characterized as being chitin. In some embodiments, the mRNA molecule to be purified contains 30-50% U nucleotides and 5-15% of the C nucleotides are modified, and the modified U nucleotides are preferably , 5-iodouridine, and the modified C nucleotide is preferably 5-iodocytidine. It may be characterized as being gin. In some embodiments, the mRNA molecule to be purified contains 0.5-5% U nucleotides and 25-35% of the C nucleotides are modified, and the modified U nucleotides are preferred. The modified C nucleotide is preferably 5-methyluridine. It may be characterized as being chitin. The mRNA molecule to be purified contains, for example, 50 to 100%, preferably 10 The modified U nucleotides are preferably is N1-methylpseudouridine.

[0051] In some embodiments of the present invention, the process further comprises, prior to step (Ia), adding ammonium acetate obtaining a suspension containing precipitated mRNA molecules. Precipitation is typically performed without salt, especially since mRNA precipitation is cost-effective and convenient. Advantageous for removing nucleotides and proteins. For example, GSCN, NH4OA c, various precipitation agents including ethanol, lithium chloride, sodium acetate and sodium chloride Such solutions are known to those skilled in the art. However, particularly for therapeutic applications, The elimination of salts such as LDS is highly advantageous. In the form, the mRNA molecules are precipitated using NHOAc. The suspension used in (Ia) is preferably NH Obtained using 4OAc.

[0052] As noted above, in some embodiments of the present invention, the first solution contains ammonium acetate. Preferably, the total amount of NH4OAc in the suspension and the first solution is 0.1 mo 1 mol / l to 5 mol / l, preferably 1 mol / l to 4 mol / l, more preferably 2 mol / l 1 mol / l to 3 mol / l, and therefore less than 5 mol / l, preferably 4 mol / l The amount of ammonium acetate is small, preferably less than 3 mol / l. This offers significant advantages in terms of time- and cost-effective downstream processing. The first solution has a pH in the range of 1 to 12, preferably 6.5 to 7.5. It may further include: In some embodiments of the present invention, the first solution contains ammonium acetate and is a suspension and The total amount of NH4OAc in the first solution is 1 mol / l to 4 mol / l, preferably It is 2mol / l~3mol / l. In some embodiments of the invention, the first solution has a pH in the range of 1 to 12, preferably 6. The suspension and the first solution have a pH in the range of 5 to 7.5 and contain ammonium acetate. The total amount of NH4OAc in the It is 3 mol / l.

[0053] In some embodiments of the present invention, the method for purifying an mRNA molecule comprises steps (II Prior to purifying the mRNA molecules using a third solution containing a chelating agent according to a), adding a fifth solution to the dissolved mRNA molecules obtained in step (Ib); The fifth solution preferably contains the same chelating agent as the third solution. The fifth solution is preferably a cation-removing solution, particularly for removing divalent cations such as magnesium cations. The mixture contains EDTA as a chelating agent for chromatin depletion and, optionally, MOPS buffer. However, the concentration of the chelating agent in the fifth solution is preferably less than that in the third solution. The concentration of the chelating agent contained in the solution obtained in step (Ib) is higher than that of the chelating agent contained in the solution. By carrying out step (IIa) after adding the fifth solution to the A molecule, step ( The composition of the solution in which the mRNA molecules obtained in Ib are suspended is The composition of the third solution used in the experiment can be adjusted to account for potential dilution effects. The effects of purifying mRNA molecules according to the methods disclosed herein can be reduced. This has the advantage that it can increase capacity and / or reproducibility.

[0054] In some embodiments of the present invention, the method for purifying an mRNA molecule comprises: Dephosphorylation and / or polyadenylation and / or post-capping Thus, mRNA molecules can be prepared using the methods of the present invention. Not only can it be purified, but it can also be used to convert mRNA molecules into functional amino acids such as proteins. It is also possible to modify the nucleic acid sequence so that it can be translated into the desired amino acid sequence. For example, in vitro synthesis or transcriptional and / or co-transcriptional 5' capping of mRNA molecules. In order to remove the 5'-monophosphate, 5'-diphosphate and / or 5'-triphosphate that are added during Dephosphorylation of mRNA molecules for the purpose of cleaving the poly(A) tail of the mRNA molecule. Polyadenylation of mRNA molecules, since this is a major determinant of lifespan; and , post-capping of mRNA molecules in the absence of co-transcriptional 5'-capping In particular, the 5' cap and 3' poly(A) tail are major factors in determining mRNA efficiency. These features are believed to be determinants of the mRNA sequence, and therefore should be incorporated into methods for purifying mRNA molecules. This maximizes the time and cost efficiency of processing mRNA molecules and the ability to synthesize purified mRNA. This is advantageous in terms of maximizing the duration of action of the molecule.

[0055] The presence of a 5' cap increases the stability of the mRNA molecule, and as a result This is advantageous for extending the duration of action of the molecule. If the RNA molecule does not contain a 5' cap or a 5' cap analog, the mRNA molecule is preferably Preferably, for example, by enzymatic addition of a C1-m7G cap or a m7GpppG cap. However, more preferably, the mRNA molecule is post-transcriptionally 5' capped, e.g. For example, using the ARCA cap analog or Trilink technology (CleanCap By applying the same In this case, the use of the TFF method according to the present invention is Useful for removing the clean cap analogue It is beneficial.

[0056] Furthermore, if the precipitated mRNA molecules to be purified do not contain a 3' poly(A) tail, The RNA molecule preferably contains at least 100 A nucleotides, preferably at least More preferably, the nucleotide sequence comprises at least 120 A nucleotides, more preferably at least 240 A nucleotides. The poly(A) tail is enzymatically polyadenylated. The poly(A) tail may be present within the poly(A) tail sequence and / or at one end of the poly(A) tail. The termini may contain nucleotides other than A, preferably G nucleotides, but the termini , should not be added to the 3' end of the mRNA molecule to be purified. A) The addition of a tail increases the duration of action of the mRNA molecule, and therefore This has been found to be advantageous in order to achieve a desired level of translation.

[0057] Thus, in some embodiments of the invention, for purifying the mRNA molecules according to the invention, The method further comprises dephosphorylating the mRNA molecule. In another embodiment of the invention, the method further comprises polyadenylating the mRNA molecule. include. In yet another embodiment of the invention, the method includes post-capping an mRNA molecule. It further includes:

[0058] In some embodiments, the method for purifying an mRNA molecule according to the present invention comprises at least: This involves dephosphorylating and polyadenylating the mRNA molecule.

[0059] In some embodiments, the method for purifying an mRNA molecule according to the present invention comprises at least: Dephosphorylating and postcapping the mRNA molecule. Phosphorylation is performed after post-capping of the mRNA molecule.

[0060] In some embodiments of the present invention, the method for purifying an mRNA molecule comprises the steps of: ) and dephosphorylating the mRNA molecule obtained in step (Ia) to (IIb) and subsequently polyadenylating the resulting mRNA molecule. and then carrying out steps (Ia) to (IIb) again, as described below. Step (Ia) is preferably carried out at a temperature between 20° C. and 30° C., preferably at a temperature between 23° C. and 27° C. , more preferably at 25° C., and optionally subsequently subjecting the resulting mRNA molecules to The retentate containing the mRNA is filtered, thus maximizing the cost- and time-effectiveness of the mRNA molecule processing. To purify the mRNA molecules, the method involves dephosphorylating and polymerizing the mRNA molecules. In particular, the latter two steps and the dephosphorylation step are included. To purify mRNA molecules to remove components introduced during transcription and polyadenylation. It has been found to be advantageous to introduce together the further steps of

[0061] Therefore, in particular, the mRNA molecules to be purified contain a 5' cap or 5' If the mRNA molecule contains a cap analog, the method for purifying the mRNA molecule comprises the steps of: First, in step (Ia), it is preferable to include ammonium acetate. The precipitated mRNA molecules are then subjected to a first solution containing the precipitated mRNA molecules. Then, in step (Ib), the purified precipitated mRNA is purified from the suspension. The molecule is then separated into a second solution, for example to remove proteins, salts and nucleoside triphosphates. The dissolved mRNA molecules are then washed and dissolved, preferably using water. 5' monophosphate, 5' diphosphate and 5' phosphate from RNA molecules that may not have been tagged It is dephosphorylated by methods known to those of skill in the art to remove the triphosphate. The folylated mRNA molecules are then subjected in a further step (Ia) to ammonium acetate. and then further steps (Ib In step (a), the substrate is washed with a second solution, preferably water. The resulting mRNA molecule is then separated in step (IIa) from the failed mRNA molecule and the dehydrated mRNA molecule. To remove the decomposition products, a third solution containing a chelating agent, preferably EDTA, is added. or MOPS at a pH of 0 to 8, more preferably 6.5 to 7.5. The third solution is then purified using the fourth solution in the washing step (IIb). For example, a poly(A) tail may be removed by carrying out a step Because a DNA template containing the sequence was used for in vitro transcription, polyadenylation was not required. If no purification step is required, the resulting purified mRNA molecules can be purified by step (IIb ) using a fourth solution preferably containing citrate and / or sodium chloride. Optionally, after step (IIb), the mixture is washed using, for example, An additional filtration step using a filter membrane with a pore size of less than 0.3 μm was performed. For example, a DNA template that does not contain a sequence encoding a poly(A) tail may be used in vitro. If a polyadenylation step is advantageous because it was used for transcription, the resulting The purified mRNA molecules are then added in step (IIb) to a fourth solution, preferably water. and then the mRNA is purified by adding, for example, poly(A) polymerase. A routine experimental protocol was employed to ensure the extension of the action of the A molecule, and the 3' poly(A) The mRNA can then be extended by enzymatically adding a tail. Preferably, step (Ia) includes, for example, removing added poly(A) polymerase. In order to achieve this, the temperature is 20°C to 30°C, preferably 23°C to 27°C, and more preferably It is preferred that the reaction be carried out at 25° C. and that the fourth solution used in step (IIb) is or purified containing a 5' cap or a 5' cap analog and a 3' poly(A) tail. except that it contains citrate and / or sodium chloride to obtain the mRNA molecule of The resulting product is then subjected to steps (Ia) to (IIb) as described above. The purified mRNA molecules may be, for example, filtered using a filter media having a pore size of less than 0.3 μm. A further filtration step using membrane may also be applied.

[0062] The mRNA molecule to be purified is cotranscriptionally added with a 5' cap or 5' cap analog In the absence of the above, the method for purifying mRNA molecules according to the present invention is , a 5' cap or a 5' cap analog is added post-transcriptionally, preferably enzymatically. Thus, the purification of mRNA molecules may include the further step of: The method may include the steps of: first, in step (Ia), ammonium acetate is The precipitated mRNA molecules are then subjected to a first solution, preferably containing a phosphate buffer. The mRNA molecules are then purified from the suspension containing the purified mRNA molecules in step (Ib). The prepared, precipitated mRNA molecules are purified, e.g., to remove proteins, salts, and nucleoside triphosphates. To remove the fluorine, a second solution, preferably water, is used to wash and dissolve the fluorine. The method further comprises capping the mRNA molecules obtained in step (Ib). and then carrying out steps (Ia) and (Ib) and eluting the resulting mRNA molecule. and then carrying out steps (Ia) to (IIb). For example, a DNA template containing a sequence encoding a poly(A) tail is transcribed in vitro. If a polyadenylation step is not required because the The purified mRNA molecules are then subjected to step (IIb) of addition of citrate and / or chloride. A fourth solution is used to wash the surface, preferably containing sodium, and optionally Following step (IIb), a filter membrane having a pore size of less than 0.3 μm may be used. An additional filtration step using a blend may be performed. For example, to remove the poly(A) tail, Because a DNA template containing no coding sequence was used for in vitro transcription, If a polyadenylation step is favored, the resulting purified mRNA molecules can be In (IIb), a fourth solution, preferably water, is used for washing, and then, for example, poly The addition of RNA polymerase ensures the extension of the mRNA molecule. By enzymatically adding a 3' poly(A) tail using standard experimental protocols. The mRNA molecule can then be subjected to steps (Ia) to (IIb). However, step (Ia) is preferably carried out by, for example, adding poly(A) polymer. In order to remove enzymes, the temperature is set to 20°C to 30°C, preferably 23°C to 27°C, more preferably Preferably, step (IIb) is carried out at 25° C. and preferably includes the step of adding citrate and / or salt. A fourth solution is used, optionally followed by the addition of sodium chloride to the resulting mR The retentate containing the NA molecules is filtered.

[0063] Thus, steps (Ia) to (IIb) preferably include 3' polyadenylation and optional Optionally, this is performed before any extension of the mRNA molecule, such as 5' capping. In particular, steps (Ia) to (IIb) preferably include 3' polyadenylation of the mRNA molecule. and steps (Ia)-(Ib) are preferably carried out before 5'-capping. This is true for all four of the above embodiments, i.e., simultaneous transcription Capped mRNA molecules and post-transcriptionally 5' capped mRNA molecules, respectively This applies when refining

[0064] Furthermore, in all four of the above embodiments, prior to carrying out steps (Ia) and (Ib), m The step of dephosphorylating the RNA molecule may be optional. In some embodiments, the mRNA molecule is dephosphorylated prior to performing steps (Ia) and (Ib). This corresponds to the above four embodiments, except for the step of converting the

[0065] TFF uses capsules, cassettes and cassette holders or hollow fibers as filter devices. In particular, hollow fiber modules can be used to perform aseptic processing. Complete, pre-assembled, pre-sterilized, disposable flow This provides a cost-effective route to packaging filter membranes. This provides a method for

[0066] The filter membranes used for the purification of mRNA molecules are suitable for the purification of mRNA molecules. It is made of any kind of material that does not interact with the mRNA molecules to be purified. Examples of filter membrane materials include unmodified polyethersulfone ( PES), modified polyethersulfone (mPES), mPES hollow fiber membrane, poly Polyvinylidene fluoride (PVDF), cellulose acetate, nitrocellulose, mixed cellulose cellulose ester (ME), ultra-high molecular weight polyethylene (UPE), polyfluorotetraethylene Polystyrene (PTFE), nylon, polysulfone (PS), polyacrylonitrile, polypropylene Polypropylene, polyvinyl chloride, polyvinylidene difluoride (PVDF) and their Combinations are possible.

[0067] Filter membranes are characterized by their molecular weight cut-off (MWCO) value and are The molecular weight cut-off (MWCO) value is the limit at which 90% of the particles are retained by the membrane. It refers to the molecular weight, in Daltons, of the smallest particle that can be measured using a filter membrane. Len is a pore size that is smaller than the MWCO and therefore the pore size. , while allowing the mRNA molecules to pass through the filter membrane as permeate. The pore size is suitable for retaining the various components of different sizes that must be removed. Therefore, the pore size of the filter membrane is adjusted in each step of the method according to the present invention. It is advantageous to adjust the size of the component to be removed.

[0068] In some embodiments of the present invention, in step (Ia), the A filter having a molecular weight cut-off of 500 kDa, preferably a molecular weight cut-off of 500 kDa. The membrane is used for TFF and / or steps (Ib) and (IIb). For this purpose, the molecular weight cutoff is 1 kDa to 0.65 μm, preferably 1 kDa to 300 kDa. a molecular weight cutoff, more preferably a molecular weight cutoff of 1 kDa to 50 kDa, More preferably, the molecular weight cutoff is 50 kDa, 70 kDa and / or 100 kDa. and / or in the case of step (IIa), a filter membrane having A molecular weight cutoff of at least 50 kDa, preferably at least 70 kDa. More preferably, the filtrate has a molecular weight cut-off of 70 kDa or 100 kDa. The filter membrane used in TFF is a filter membrane. - The pore size of the membrane allows the particles to pass through the filter membrane, resulting in This is important because it determines the size of particles, such as mRNA molecules and components, contained in the permeate. do.

[0069] Therefore, the MWCO of the filter membrane is preferably, for step (Ia), The MWCO is at least 300 kDa or 0.065 μm. kDa, 500kDa, 750kDa, 0.05μm, 0.1μm, 0.2μm, 0.4 5 μm, 0.5 μm, 0.65 μm, and having a MWCO of 500 kDa. This is particularly preferred, for example, for the preparation of lysed cells from which mRNA molecules are to be purified. of in vitro transcribed mRNA molecules while removing enzymes and proteins involved In some cases, the enzymes included in the in vitro transcription reaction mixture, the modified triphosphate nucleotides, Nucleosides and unmodified triphosphates, 5' caps, 5' cap analogs and This is advantageous for retaining the precipitated mRNA molecules while removing buffer components. Therefore, an appropriate MWCO value is determined, for example, prior to in vitro transcription of the mRNA molecules to be purified. of the enzyme used in the treatment step to be removed by TFF in step (Ia) Size considerations can be used to select the desired RNA polymerase. When using filter membranes with a MWCO of less than 100 kDa, In step (Ia), 1 kDa is an enzyme well known in the art that is not removed. When MWCOs in the ~750 kDa range are used, TFF is sometimes called ultrafiltration. On the other hand, when MWCO in the range of 0.05 μm to 0.65 μm is used, the TFF is This is also called microfiltration.

[0070] For steps (Ib) and (IIb), the MWCO is preferably at least 1 kDa. , preferably 1 kDa to 50 kDa, more preferably at least 50 kDa, and even more preferably Preferably, the MWCO is at least 70 kDa. Preferably, the MWCO is 1 kDa, 3 kDa, , 5kDa, 10kDa, 30kDa, 50kDa, 70kDa, 100kDa, 300 kDa, 0.05 μm, 0.1 μm, 0.2 μm, 0.45 μm, 0.5 μm and 0.6 5 μm, and having a MWCO of 50 kDa, 70 kDa or 100 kDa. Particularly preferred are ammonium acetate, chelating agents such as EDTA, and buffers such as MOPS. buffers, failed mRNA molecules and / or hydrolysis products, salts and It is advantageous for purifying mRNA molecules while efficiently removing other components. For larger mRNA molecules, a MWCO of greater than 300 kDa may be considered.

[0071] In the case of step (IIa), the MWCO is preferably at least 50 kDa, more preferably at least 50 kDa. or at least 70 kDa, even more preferably 70 kDa or 100 kDa. For example, when using the above MOPS-EDTA buffer, the MWCO is 100 kDa. Particularly preferred are other strong chelating agents or combinations of other strong chelating agents with buffers. When a method is employed, even a MWCO of 100 kDa or more may be required for the analysis of relatively large mRNA molecules. It may be considered for purification.

[0072] Furthermore, processes using TFF can be characterized in terms of various variables. However, the two most important variables are transmembrane pressure and flux.

[0073] "Transmembrane Pressure" (TMP) is the driving force that forces components through the filter membrane. In some embodiments, the transmembrane pressure is For example, in a typical laboratory scale case of 500 mg of mRNA, 00mbar to 500mbar, preferably 200mbar to 400mbar. In the case of steps (IIa) and (IIb), the pressure is from 2 mbar to 20 mbar, preferably The pressure is usually between 5mbar and 15mbar.

[0074] The term "flow" refers to the flow through a TFF system, particularly the "Flow rate" refers to the volume of solution flowing through the membrane area of ​​the system during a given period of time. The flow rate or crossflow velocity is the rate at which the solution flows through the filter. In some embodiments, the flow rate refers to the rate at which the flow passes across a flow membrane. The flow rate for the cases of (Ia) and (Ib) is, for example, 500 mg / m in a typical case. At the laboratory scale, the flow rate is 1.5L / min to 2.5L / min, preferably 1 .6L / min to 1.9L / min, and in the case of steps (IIa) and (IIb) , 0.2L / min to 0.6L / min, preferably 0.35L / min to 0.45L / min min.

[0075] In a particularly preferred embodiment of the present invention, the method for purifying mRNA molecules comprises the steps of a continuous T Continuous TFF is performed using a continuous TFF system in which the retentate is fed to another TFF cycle. As used herein, the term "feed" refers to a TFF system. It refers to a solution or suspension containing the mRNA molecules to be purified. The initial feed containing the mRNA was subjected to a first round of filtration using TFF, and the resulting mRNA molecules were The retentate containing at least one mRNA molecule is then circulated to produce another round of TFF. This is because the mRNA fragmentation caused by the transfer between systems is The level of purification is increased by repeating the purification steps automatically while reducing the risk of child loss. This is advantageous for improving the

[0076] Thus, in some embodiments of the invention, the mRNA molecules are purified by tangential flow filtration. The retentate obtained by steps (Ia) to (IIa) is preferably contained in the retentate obtained by steps (Ia) to (IIa). In the case of step (IIb), the mRNA molecules are at least contained in the retentate or permeate. It may be included in the excess. In some embodiments, the mRNA molecule is produced by steps (Ia) to (IIb). contained in the obtained retentate.

[0077] In some embodiments of the present invention, the retentate obtained in step (Ia) is In (Ib), it is used as a feed solution for tangential flow filtration and The retentate obtained in step (Ib) is mixed with the feed solution in step (IIa). The retentate obtained in step (IIa) is used as a catalyst in step (IIb). Therefore, the present invention preferably comprises at least one A continuous TFF is used to carry out steps (Ia) to (IIb). More precisely, the mRNA molecules are preferably subjected to a continuous TFF system for purification according to the present invention. Thus, in one embodiment of the present invention, at least step (I Steps (a) to (IIa), preferably steps (Ia) to (IIb), are carried out using a continuous TFF. It will be implemented.

[0078] An additional advantage of the TFF system is that it is ideal for diafiltration, especially The advantage is that it can be easily used for continuous diafiltration. Filtration is the exchange of part of a solution or suspension with another solution or suspension. For example, in discontinuous diafiltration, the solution is first diluted This is then concentrated back to the original volume. This may adversely affect the functionality of the NA molecule.

[0079] Thus, in a preferred embodiment of the present invention, the mRNA molecule to be purified comprises at least Between steps (Ia) and (IIb), the above-mentioned constant volume diafiltration was used. It is circulated in a continuous TFF system for purification by the method. Constant volume or continuous Diafiltration is a filtration process in which a constant volume is maintained within the filtration system. It therefore refers to the volume of a solution or suspension that passes through a filter membrane as permeate. The same amount of solution or suspension is added as the initial volume of the TFF system. The volume supplied to the stem, i.e., the feed volume, is the same as the wash volume. g volume, i.e., diafiltration volume The volume on volume is the same as the volume of the permeate. Combining filtration with TFF allows the purification of the mRNA in the circulation part of the TFF system. The NA molecules are permeated while maintaining a constant volume to preserve the function of these mRNA molecules. It is advantageous to remove contaminants as a permeate.

[0080] Thus, in some embodiments of the present invention, at least steps (Ia) to (IIa) Preferably steps (Ia) to (IIb) are carried out by diafiltration, preferably This is carried out using continuous diafiltration.

[0081] In some embodiments of the present invention, any of the first, second, third and / or fourth solutions may be The filtration volume should be at least 1x the volume of the suspension in step (Ia). For example, 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, preferably at least 10-fold. The amount of filtration to be performed is determined by balancing time and cost effectiveness with the production level to be achieved. It is of particular interest in terms of the optimal trade-off between the first, second, and third and / or the diafiltration volume of any of the fourth solutions of step (Ia) It is found that the volume of the suspension is at least 1-fold, preferably at least 10-fold. This allows for high-throughput processing and therefore large-scale purification of mRNA molecules. However, it is advantageous to ensure substantial removal of the components.

[0082] In some embodiments, the diafiltration volume is the volume of the suspension of step (Ia). The precipitated tetrahydrofuran (TFF) system was initially fed in step (Ia) to the TFF system. It is 1x the volume of the suspension containing the mRNA molecules. In some embodiments, the diafiltration volume is 2 times the volume of the suspension. . In some embodiments, the diafiltration volume is 3 times the volume of the suspension. . In some embodiments, the diafiltration volume is 4 times the volume of the suspension. . In some embodiments, the diafiltration volume is 5 times the volume of the suspension. . In some further embodiments, the diafiltration volume is the suspension volume of step (Ia). At least 5 times the volume of the liquid.

[0083] In some embodiments, the diafiltration volume is the volume of the suspension of step (Ia). The precipitated tetrahydrofuran (TFF) system was initially fed in step (Ia) to the TFF system. The volume of the suspension containing the mRNA molecules is at least 10 times that of the suspension containing the mRNA molecules. Using a diafiltration volume of at least 10 times the volume fed is an advantage over the above-mentioned It has been found to be advantageous to substantially remove the components of interest in a step.

[0084] Thus, the diafiltration trays of any of the first, second, third and / or fourth solutions The volume of the suspension is preferably at least 10 times the volume of the suspension in step (Ia). Preferably, the diafiltration volumes of the third and fourth solutions are at least equal to or greater than the steps ( Even more preferably it is at least 10 times the volume of the suspension of Ia).

[0085] In some embodiments, the diafiltration volumes of the first, second, third and fourth solutions are is at least 10 times the volume of the suspension of step (Ia).

[0086] A fully automatable clone to obtain purified mRNA molecules by the method of the present invention A system similar to that described above is shown by way of example in FIG. The system is in fluid communication with the first valve, preferably in fluid communication with the second valve. It should be noted that the term "continuous TFF" used in this specification The term "valve" includes valves, (e.g., two-way and / or three-way) cocks, clamps and MPC connectors are preferred; valves and / or MPC connectors are preferred. The connector is preferably used in combination with a clamp. The material, e.g., two tubes, allows for disposable and / or compatibility with various systems. , e.g., stability to high pressure and / or pressure changes in one of the tubes; and and / or may be connected in a manner that ensures low cost.

[0087] The mRNA production system may include a reaction vessel and at least one further vessel. The reaction vessel and the at least one further vessel are preferably in fluid communication with each other via a connecting pipe. The first valve is in fluid communication with the mRNA production system. The system connecting tubing and the tubing of the TFF system, preferably from the feed reservoir to the filter Alternatively, the mRNA production system may be The filter device may be in fluid communication with a tube that circulates from the filter device to the reservoir, or the reservoir and the fluid It should be noted that the term "tube" as used herein may refer to a pipe, a tube, a piping, or a combination thereof. The connecting pipe may include an auxiliary pump. The auxiliary pump is arranged to pump the liquid through the connecting pipe. It is advantageous to automatically regulate the velocity of the fluid.

[0088] The mRNA molecules to be purified by the method of the present invention can be, for example, It can be obtained by culturing cells or, preferably, by in vitro transcription (I When the mRNA molecule is obtained from a cell, it can be obtained by E. coli (E. The cells, such as Escherichia coli cells, are grown under cell-specific culture conditions suitable for the production of mRNA molecules. The culture conditions may be preferably, for example, Automatically regulates by supplying the respective amount of medium, gas and / or buffer. Thus, the mRNA production system comprises a reaction vessel and at least one further vessel. wherein the reaction vessel is a fermenter and the at least one further vessel is, for example Each medium, gas and / or buffer solution is included.

[0089] Alternatively, if the mRNA molecules to be purified are obtained by IVT, the IVT template, e.g. For example, each DNA template for IVT of the target mRNA molecule to be purified and Enzymes, such as T7 RNA polymerase and IVT reagents, such as a mixture of NTPs, are required. will be done.

[0090] Thus, the mRNA production system comprises a reaction vessel and at least one further vessel. and at least one further container may contain at least one of said IVT reagents. Includes one.

[0091] Therefore, the reaction vessel preferably contains at least one further vessel, preferably at least The fluid communication port is in fluid communication with at least a first further container and a second further container.

[0092] A first further container may contain at least one of said IVT reagents, and is preferred. Preferably, the reaction vessel is in fluid communication with the reaction vessel via the connecting pipe and the second and third valves. Alternatively, the second valve is disposed between the reaction vessel and the connecting pipe, and the third valve is The first valve is closed, and the second and By opening the valve 3, the mRNA molecules are preferably reacted, for example by IVT. The third valve is closed and the first and second valves are opened. The produced mRNA molecules are transferred from the mRNA production system to the TFF system. It is possible.

[0093] A second further container may contain a solution for precipitating the mRNA molecules, said solution The solution preferably contains ammonium acetate (NH4OAc), e.g. 5M NH4OAc. Preferably, the second further container is in fluid communication with the manifold via a fourth valve. The second and fourth valves are opened and the first and third valves are closed to obtain the target The molecules can be precipitated in the reaction vessel or, if the reaction vessel is a fermenter, in a second The first valve is then opened, and the suspension is allowed to settle in a further vessel. The precipitated mRNA molecules are purified by the method of the present invention from the mRNA production system. The resulting mixture can then be transferred to a TFF system for further purification.

[0094] Thus, the system shown in FIG. 2 is a TFF system having a reservoir, preferably A continuous diafiltration system is provided. Preferably, the reservoirs each contain at least At least three further containers, i.e., via at least the fifth, sixth and seventh valves, That is, at least a third additional vessel, a fourth additional vessel, and a fifth additional vessel and The third further container may contain a first solution according to the invention, and the fourth A further container may contain a second solution according to the invention and a fifth further container may contain a It may contain a third solution according to the invention. If the second and fourth solutions are different, the reservoir The fourth solution is preferably in fluid communication with a sixth further vessel, for example via an eighth valve. Thus, the third additional container contains a first solution, and the first solution is , NH4OAc for purifying precipitated mRNA molecules, e.g. 2.5M NH4OAc and a fourth additional container contains water as the second solution, e.g., water for injection (WFI). and a fifth additional container contains a third solution, the third solution containing as a chelating agent It preferably contains EDTA and optionally MOPS. If the fourth solution is not water, In this case, the sixth further container preferably contains sodium chloride and / or sodium citrate. Further, the auxiliary pump may be configured to pump the liquid from any of the at least three additional containers to the reservoir. The valve may be present to automatically adjust the rate at which fluid is transferred to the valve.

[0095] Thus, the reservoir preferably has a first valve open for a predetermined length of time. The suspension is transferred from the mRNA production system through the first valve by placing the The fifth valve is left open for a predetermined length of time, containing the precipitated mRNA molecules. adding the first solution to the precipitated mRNA molecules in suspension; The mixture is then passed through a filter device for at least one continuous TFF cycle. The filter membrane is preferably between 300 kDa and 0. It has a molecular weight cutoff of 65 μm. Therefore, the suspension containing the precipitated mRNA molecules is prepared by step (Ia) of the method disclosed herein, e.g. by extracting proteins, salts and / or It can be purified from components of the IVT mixture such as NTPs. Purified precipitated mRNA The suspension containing the molecules is preferably returned to the reservoir as a retentate. Therefore, the purified precipitated mRNA obtained in step (Ia) is To wash and dissolve the A molecules, the sixth valve is opened for a predetermined length of time. As a result, the second solution is added to the suspension containing the precipitated mRNA molecules in the reservoir. A filter media with a molecular weight cutoff of 1 kDa to 0.65 μm can be added. A filter device, preferably having a membrane, is used to filter the sieve in at least one revolution. For example, NH4OAc contained in the first solution can be removed by carrying out a subsequent TFF. The seventh valve can then be opened for a predetermined amount of time. This allows the third solution to be added to the washed and lysed mRNA molecules in the reservoir. The filter membrane preferably has a molecular weight of 50 kDa, more preferably 100 kDa. At least one continuous TFF run was performed using a filter device with a cut-off By carrying out the above steps, the failed mRNA molecules and the hydrolysis products of the mRNA molecules are isolated according to the present invention. It can be efficiently removed by step (IIa) of the method disclosed herein. For example, The purified cellulose obtained in step (IIa) is obtained by removing the components of the third solution. Step (IIb) may then be performed to wash the isolated mRNA molecules. Therefore, the sixth or eighth valve may be a filter with a molecular weight cutoff of 50 kDa. Perform at least one continuous TFF cycle using a filter device with a membrane. A fourth solution containing water or sodium chloride and / or sodium citrate for the purpose of The solution is opened for a predetermined length of time to add to the purified mRNA molecules. do.

[0096] Optionally, a further step is carried out between step (Ib) and step (IIa). Therefore, the TFF system is preferably implemented by, for example, The system may further comprise a seventh further container in fluid communication with the reservoir. The container may contain a fifth solution, which preferably contains at least the third solution. The solution contains a chelating agent, preferably EDTA, in a higher concentration than in the third solution. Opening the ninth valve for a predetermined length of time after performing step (Ib). The fifth solution can then be added to the mRNA molecules dissolved in the second solution. The concentration of at least the chelating agent in the TFF system is defined as the third by shortening the time required to adjust to each specified concentration in relation to the solution of This has the advantage that the throughput and reproducibility of the method of the invention can be increased. An auxiliary pump automatically regulates the rate at which fluid is transferred from a seventh additional container to a reservoir (not shown). It may be present to dynamically adjust.

[0097] Optionally, the mRNA molecule production system can be configured to selectively deliver the mRNA via a temporary valve. a temporary storage container, preferably in fluid communication with a connecting tube of the RNA molecule production system; The temporary container may be a bag, which is preferably sterile. By keeping the first valve and the temporary placement valve open for a certain period of time, the mRNA At least a portion of the suspension or solution containing the molecules is removed from the TFF system to produce mRNA molecules. Transfer to the TFF system and / or from the mRNA molecule production system to the TFF system. This can be done by allowing the suspension or solution to dry for a period of time, preferably over a period of time. It may be advantageous to store at least a portion of the suspension or solution. The at least a portion may be subjected to a further round of purification, e.g., steps (Ia) and (Ib). , may not be subjected to steps (IIa) and (IIb) and / or combinations thereof. Further, while at least a portion of the suspension or solution is stored in the temporary storage container, the TF F system and / or mRNA molecule production system, and Optionally or alternatively, the device may be washed and / or sterilized with a buffer. The temporary storage container contains a solution or suspension, preferably a purified mRNA molecule. It can be used to obtain at least a portion of the solution or suspension containing Thus, the system can further include a filter (not shown) for an additional filtration step. The filter may comprise a filter having a particle size of less than 0.3 μm, e.g., 0. The container may be provided with a filter membrane with a pore size of 0.22 μm, so that the container can be easily removed from the container. This may be useful for the final filtration of the suspension containing the purified mRNA molecules obtained from the

[0098] The mRNA molecule to be purified may be, for example, dephosphorylated and dephosphorylated with a 5' cap and / or a 3' poly( A) It may be advantageous to modify the peptide by adding a tail. The sequences (Ia) to (IIb) are preferably located at least one position prior to the 3' polyadenylation of the mRNA molecule. Each step is preferably carried out once, and steps (Ia) and (Ib) are preferably carried out once before 5'-capping. Optionally, the resulting mRNA molecules are subjected to at least one round of amplification. Dephosphorylated after the second step (Ia) and at least the first step (Ib) Then, at least a second step (Ia) and at least a second step (I The system can therefore include one of the following (not shown): It may further comprise one or more of: preferably including reagents necessary for capping, preferably Preferably, the fourth valve is in fluid communication with the connecting pipe of the mRNA production system. 2' a further container, preferably containing the reagents necessary for dephosphorylation, preferably A second '' Further containers and preferably reagents necessary for enzymatically adding a poly(A) tail, e.g. For example, the enzyme may contain at least poly(A) polymerase, preferably via a fourth valve. A second''' additional container in fluid communication with the connecting tube of the mRNA production system. The first valve and the temporary valve are opened for a length of time to purify the mixture. At least a portion of each suspension containing mRNA molecules should be extracted from the TFF system. The first valve is closed, and the fourth valve is opened. By opening the 'and / or fourth' valves, the mRNA molecules are capped, decapsulated, and Phosphorylation and / or polyadenylation can be preferably carried out in a temporary vessel. Alternatively or additionally, if the reaction vessel is not a fermenter, the reaction vessel may be used as a temporary storage vessel. It can be used as a replacement for the temporary valve and therefore as a second valve instead of the temporary valve. Valves 4', 4'' and / or 4'' are closed and valve 1 is open. By opening the tube, the suspension containing the modified mRNA molecules is introduced into the mRNA molecule production system. The system can be transferred from the TFF system to the

[0099] Please note that the filter unit may contain more than one filter member that can be automatically replaced. Preferably, the filter devices are, for example, The mRNA molecules are subjected to a continuous TFF process. For the above, the molecular weight cutoffs are specified in connection with each process step. The mixture is transferred to at least one of the filter device units, which includes a filter membrane. can be.

[0100] Further, as shown in FIG. 2, the system may include, for example, a tenth valve. Preferably, the outlet is in fluid communication with the reservoir via an outlet port, e.g., an outlet receptacle. The mouth container stores at least a portion of the solution or suspension containing the purified mRNA molecules. refers to or is in fluid communication with a sterile, preferably disposable, bag for By opening the tenth valve, the purified mRNA molecules can be obtained. Alternatively, in step (IIb) (which is carried out last), the purified mRNA fragment is The molecules may be contained in the permeate rather than the retentate. Optionally, the system further comprises: The method may further include a filter (not shown) for the filtration step. - has a pore size of less than 0.3 μm, e.g. 0.22 μm, for the final filtration step The suspension may be provided with a filter membrane, and thus contains purified mRNA molecules. It may be useful for final filtration of the liquid, e.g. the permeate, or the suspension obtained from the outlet vessel. Additionally, an auxiliary pump automatically regulates the instantaneous rate at which fluid is transferred from the reservoir to the outlet (not shown). The amine may be present to selectively regulate

[0101] The system includes a cooling element and / or a heating element (FIG. The cooling and / or heating elements may further comprise a tube, a vessel (e.g., , reaction vessels, temporary storage vessels, further vessels and / or reservoirs) and / or filter devices. The second electrode may be disposed so as to at least partially surround one or more of the first electrode and the second electrode. The cooling element is disposed to at least partially surround the reservoir and / or the filter device. The method according to the invention therefore involves the control of each cooling and / or heating element. Therefore, it is possible to carry out the reaction at a temperature between 0°C and 25°C, and preferably, most of the steps are carried out at a temperature between 0°C and 25°C. The purification of methane can be performed at 2°C to 8°C. RNA molecules can be obtained.

[0102] Preferably, the system includes a pH control component which is preferably automatically controlled. The element may further comprise a measuring element (not shown) for measuring the concentration of the solution and / or suspension, such as a pH meter. A device for measuring pH and optionally a pH adjustment vessel may be provided, as described below. The pH adjustment vessel is preferably a vessel (e.g., a reaction vessel, a temporary storage vessel, a further vessel and / or or reservoir). Thus, the solution in each of the containers Additionally or alternatively, the pH of the suspension may be measured and / or controlled. In the present invention, the pH of the permeate can be measured, preferably continuously. Therefore, the mRNA purification process can be monitored and quality checked. This can be done.

[0103] Additionally, the concentration and / or purity of the nucleic acid can be measured, preferably using the permeate. Such measurements can be performed by measuring the absorbance of molecules, including mRNA molecules, at about 260 nm in the UV range. This can be done photometrically by measuring at 280 nm and 280 nm. For example, the quotient of the value obtained at about 260 nm to the value obtained at about 280 nm is For example, a ratio of about 1.8 to about 2.0 indicates high purity. A ratio of less than 1.8 may indicate a high degree of DNA or RNA synthesis, whereas a ratio of less than 1.8 may indicate a high degree of protein synthesis. Thus, for example, information on the composition of the permeate can be used to Optionally or alternatively, the concentration of mRNA molecules can also be obtained. The concentration can be determined by conductivity measurements, preferably continuous conductivity measurements. Thus, the system may include a spectrometer and / or a spectrophotometer, such as a nanodrometer. Preferably, the means for performing the measurement of the conductivity, the operation of the device, and / or the measurement of the conductivity are automatically controlled. It may further comprise elements for nucleic acid quantification (not shown).

[0104] Any one of the containers (e.g., reaction vessels, temporary storage containers, further containers and / or reservoirs) One or all of the containers may be placed on each scale. The weight of each container is then The weight of the solution or suspension containing the mRNA molecules to be purified or to be purified in each vessel is measured. For example, each of the first, second, third, fourth and / or fifth solutions may be The appropriate amount of solution or each added component and / or IVT reagent. The production and / or purification process can be optimized and automated.

[0105] To ensure automated control of the mRNA production and / or purification process, the system is preferably Preferably, control means are arranged to control said means, e.g. valves, (auxiliary) pumps. a heating element and / or a cooling element, an element for adjusting pH, an element for quantifying nucleic acids, The system includes a means and / or a balance for carrying out conductivity measurements. The term "system" is meant to be understood as a device and may be used interchangeably with device. It can be used.

[0106] Regarding the connecting tube of the mRNA molecule production system, the connecting tube may be, for example, a reaction vessel and 2, which provides direct fluid communication with a vessel comprising In the present specification, the term "connecting pipe" may refer to two or more pipes connecting the respective containers. For example, at least a first tube that fluidly connects the reaction vessel to a first further vessel, and , may refer to a second tube that fluidly connects the reaction vessel to a second additional vessel. One or more of the two or more pipes may include a valve between each vessel and, optionally, an auxiliary port. The pressure sensor may also include a pump.

[0107] Any one of the components of the above system may be a disposable component. or one or more of the containers (e.g., temporary storage containers, reaction containers and / or further containers). One or more of the top and / or (temporary) valves are provided for each disposable container and Preferably, the temporary storage container and / or the reaction container are each a disposable container. Optionally, the entire system can be used to, for example, produce and purify a particular mRNA molecule. This may be a disposable system that is intended for use in a variety of situations, without the usual risk of contamination. The time-consuming and costly washing, cleaning and / or disinfection required to reduce Each mRNA molecule can be produced and purified under sterile conditions, eliminating the microbial step. Therefore, preferably, one or more components of the system An element is each disposable component.

[0108] The system shown by way of example in FIG. 2 has several advantages. In the ELISA system, the risk of contamination by RNases, for example, is minimized and at the same time Continuous TFF avoids clogging of the filter membrane, thus increasing throughput. Moreover, such a system can be controlled by, for example, a pump. The fluid transport is easy to handle, e.g. by (auxiliary) pumps and It is even possible to fully automate the process by automatically controlling the flow and / or valves. Moreover, such a system can be easily scaled and provides customer-specific Therefore, the high throughput of mRNA molecules can be well regulated according to the requirements of the target organism. Put purification can be performed in a highly efficient and automated manner according to the methods of the present disclosure using the system shown in FIG. The method can be carried out in an automated manner.

[0109] The present invention relates to a method for purifying an mRNA molecule, comprising: (a) purifying an mRNA molecule by the above-mentioned method for purifying an mRNA molecule; (b) incorporating the mRNA molecule thus obtained into a pharmaceutical composition. The present invention further relates to a method for producing a pharmaceutical composition comprising the steps of: The loss or defect is associated with a disease and / or the presence of the protein is mRNA molecules to enable the synthesis of proteins that are needed or beneficial in Of particular interest is the use of purified mRNA molecules in pharmaceutical applications, such as for the administration of This is profound.

[0110] Preferably, the amino acid sequence that can be translated from the mRNA molecule purified according to the present invention is The function is required or beneficial within or near a cell, e.g. In the vicinity of cells, the absence or deletion of the amino acid sequence is a cause of disease or The cause of the disease and provision of the amino acid sequence alleviates or prevents the disease or illness. or amino acid sequences that can promote beneficial processes in the body. The amino acid sequence is needed or beneficial in or near the cell. The modified amino acid sequence may be a complete amino acid sequence or a functional variant thereof. In addition, the encoded amino acid sequence may be a factor, inducer, regulator, stimulator, or or an enzyme or a functional fragment thereof, The acid sequences are intended to treat disorders of the function, particularly metabolic disorders, or to induce the formation of new blood vessels, tissues, etc. A functional amino acid sequence is a sequence of amino acids that is necessary to initiate an in vivo process, such as the synthesis of a protein. A functional variant is one that is required for the function of the amino acid sequence in a cell or that does not have the amino acid sequence. The deletion or deletion of the sequence is pathogenic, and the function of the amino acid sequence is suppressed in the cell. It is understood to mean to bear, to fragment.

[0111] Preferably, such amino acid sequences are generated by biosynthesis of suboptimal amino acid sequences. to generate or regenerate physiological functions that may have a direct or indirect effect on the course of a disease; It is advantageous for use as a supplement or for medical purposes to have a favorable effect on Disorders with a known genetic basis include, for example, cystic fibrosis, hemophilia, hypertension, cholesterol. These include elevated teratogenic levels, cancer, neurodegenerative disorders and psychiatric disorders. Currently 22,993 cases Entries for human genes and genetic disorders are provided with descriptions of each gene and phenotype. The online catalogue included in the book is ONIM (Online Mendelian Inheritance in Man webpage (http: / / onim.o rg); the respective sequences are available in the Uniprot database (http: / / www.uniprot.org / ). Available at: / / www.uniprot.org. Non-limiting examples include: Table 2 lists some congenital disorders and the corresponding genes. Cell Signaling Because pathways are highly interactive, mutations in specific genes can lead to a variety of pathological symptoms. These pathological symptoms are listed in Table 2.

[0112] Proteins also have the potential to induce immunogenic responses and act as antigens, for example. Such proteins may be used as supplements or for medical purposes, including vaccinations. This will contribute to the above.

[0113] [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] [Table 2-8] [Table 2-9] [Table 2-10]

[0114] Regarding the step of purifying the mRNA molecules, the same as described above is carried out (I a) using a first solution to separate precipitated mRNA molecules from a suspension containing the precipitated mRNA molecules; (Ib) purifying the molecule in step (Ia) using a second solution. washing and dissolving the purified precipitated mRNA molecules obtained by the above steps; ) In step (Ib), a third solution containing a chelating agent such as EDTA is used. Purifying the mRNA molecules from the resulting dissolved mRNA molecules, followed by (II b) using the fourth solution to purify the purified mRNA obtained in step (IIa); and washing the molecule, The method of claim 1, wherein steps (Ia) to (IIb) are carried out using tangential flow filtration. Also applies.

[0115] The purified mRNA molecule thus obtained is then incorporated into a pharmaceutical composition. In this regard, the step comprises the step (IIb) of purifying the mRNA molecule using water. and step (IIb) is carried out once. In some cases, it is used as the fourth solution in the final step (IIb). In each case, sodium chloride or sodium citrate should be added. This may include removing the purified mRNA molecule from sodium chloride or sodium citrate. If the purified mRNA molecule is not available in a solution that already contains chloride, It already contains sodium or sodium citrate, but what is the desired concentration for administration? It is advantageous if the compound is obtained in a solution containing the compound at a different concentration. In the latter case, the method may further comprise the step of measuring the respective concentrations and adjusting them if necessary. The purified mRNA molecules were diluted with sodium chloride or sodium citrate at the respective concentrations. A fourth solution containing ammonium chloride and having a pH of 3 to 6, preferably a pH of 4 to 5, is added to the above-mentioned mRNA molecule. for administration by use in the (last) step (IIb) of the method for Advantageous concentrations of sodium chloride or sodium citrate are further included in the solution.

[0116] The resulting purified mRNA molecule can be incorporated into a pharmaceutical composition to provide a pharma- ceutically acceptable The purified mRNA molecule is preferably in an effective amount i.e., sufficient to induce a detectable therapeutic response in the subject to which the pharmaceutical composition is administered. The purified mRNA molecule and / or pharmaceutical composition may be in a sterile aqueous solution or It can be non-aqueous solutions, suspensions and emulsions as well as creams and suppositories, but can also be powders, tablets or It may also be in the form of an aerosol.

[0117] As used herein, the term "pharmaceutically acceptable carrier" means a carrier that is In the reasonable opinion of medical judgement, excessive toxicity, irritation, allergic reaction or other problems or complications may occur. Suitable for use in contact with human and animal tissues without causing any ill effects; It refers to a compound, material, ingredient and / or composition that is reasonably priced for its risk. Acceptable carriers should be selected based on administration, adsorption, solubility, or pharmacokinetic considerations. It is an inactive substance that is compounded with a pharma- ceutical active substance for ease of handling.

[0118] Examples of suitable pharma- ceutically acceptable carriers are well known in the art and include phosphate buffered saline. Saline solutions, buffer solutions, water, emulsions such as oil / water emulsions, various species In particular, aqueous carriers include saline and buffered media. Non-aqueous solvents include water, alcoholic / aqueous solutions, emulsions or suspensions. Examples of such glycols include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and and organic esters such as ethyl oleate. Further examples of pharma- ceutically acceptable carriers are These include, but are not limited to, saline, Ringer's solution, dextrose solution, sucrose solution, tritrates, phosphates and other organic acids; counterions forming salts, e.g., sodium iodo ion and potassium ion; low molecular weight (more than 10 amino acid residues) polypeptide; protein Substances such as serum albumin or gelatin; hydrophilic polymers such as polyvinylpyrrolidone; Lysine; histidine, glutamine, lysine, asparagine, arginine or glycine Amino acids such as glucose, mannose or dextrin; monosaccharides; disaccharides Sugars; other sugars, such as sucrose, mannitol, trehalose or sorbitol; Chelating agents, such as EDTA; non-ionic surfactants, such as those available under the trade name Tween; Commercially available polyoxyethylene sorbitan monolaurate, propylene glycol, Pluronics or polyethylene glycol; methionine, ascorbic acid and antioxidants, including tocopherol; and / or preservatives, such as octadecyl dimethyl Benzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride , benzethonium chloride, phenol alcohol, butyl alcohol or benzyl Alcohol, alkylparaben, such as methylparaben or propylparaben, catechol Coal, resorcinol, cyclohexanol, 3-pentanol and m-cresol) Suitable pharma- ceutically acceptable carriers and the formulation of these carriers are described in Re. minton's Pharmaceutical Sciences, 17th edition, 1 985, Mack Publishing Co., Inc., 1999. For example, antibacterial agents, antioxidants, chelating agents and inert gases, nanosystems Preservatives, stabilizers and other additives, such as the glycerol-containing formulation (such as a glycerol-containing formulation), ... or liposomes, may also be present.

[0119] The present invention relates to a compound produced by the above-mentioned method and by any of the methods disclosed herein. The present invention further relates to a pharmaceutical composition comprising the purified mRNA molecule. and / or modulates the translation of an amino acid sequence, such as a protein, in the cells of a subject to which the compound is administered. It is advantageous to improve the quality of life of a patient by improving ... is beneficial and / or required by the subject in the context of

[0120] With respect to pharmaceutical compositions, mRNA molecules, purification of mRNA molecules and formulation of pharmaceutical compositions, see above. The same as described above, including the features and advantages mentioned in connection with each of the embodiments described above. The following applies.

[0121] The pharmaceutical compositions of the present invention can be administered by needle injection, inhalation, nebulizer, cream, foam, By a wide variety of dosage forms and routes of administration known to those skilled in the art, including gels, lotions, and ointments. The dosage and duration of action can be determined based on the efficacy of the purified mRNA molecule. It depends on the function to be performed, but in any case it must be adjusted in a planned manner. The duration of action can be determined, for example, by whether the purified mRNA molecule is capable of inhibiting a disease caused by a defective gene. When used for long-term treatment of In this case, the duration of action can be adjusted to a specific time frame. Systemic administration of the purified mRNA molecules formulated in a composition is also possible. [Brief description of the drawings]

[0122] [Figure 1]Schematic diagram of a continuous tangential flow filtration (TFF) system circulating mRNA molecules according to the disclosed method, in which the mRNA molecules are in suspension in step (Ia), in solution in step (Ib), and in solution in each case in steps (IIa) and (IIb). [Diagram 2] FIG. 1 is a schematic diagram of an exemplary system for purifying mRNA molecules by the method of the present disclosure (the position of valves, (auxiliary) pumps and / or (additional) vessels are shown as examples). [Diagram 3] After purification of each in vitro transcription (IVT) mixture at RT by steps (Ia) and (Ib), the TFF retentate containing unmodified tdTomato-encoding mRNA was subjected to SDS-PAGE followed by colloidal Coomassie staining. Lane 1: enzyme mix in ammonium acetate (NH4OAc) as a control; lane 2: enzyme mix after priming the TFF system; lane 3: enzyme mix after TFF in nuclease-free water; lane 4: IVT mix; lane 5: IVT mix after priming the TFF system; lane 6: IVT mix after TFF in nuclease-free water; lane 7: enzyme mix in nuclease-free water as a control. The enzyme mix consisted of RNase inhibitor, T7 RNA polymerase, inorganic pyrophosphatase and DNase I. [Figure 4]After purification of each in vitro transcription (IVT) mixture at RT by steps (Ia) and (b), the TFF retentate containing unmodified tdTomato-encoding mRNA was subjected to SDS-PAGE followed by colloidal Coomassie staining. Lane 1: enzyme mixture in nuclease-free water as a control; lane 2: IVT mixture before TFF; lane 3: IVT mixture after priming of the TFF system; lane 4: IVT mixture after TFF in nuclease-free water; lane 5: IVT mixture after TFF in nuclease-free water (after diafiltration with 2.5 M ammonium acetate and nuclease-free water, each mixture was concentrated 2.5-fold to efficiently detect protein removal). The enzyme mixture consisted of RNase inhibitor, T7 RNA polymerase, inorganic pyrophosphatase, and DNase I. [Diagram 5] After purification of each in vitro transcription (IVT) mixture at 4°C by steps (Ia) and (b), the TFF retentate containing unmodified tdTomato-encoding mRNA was subjected to SDS-PAGE followed by colloidal Coomassie staining. Lane 1: enzyme mixture in nuclease-free water as a control; lane 2: IVT mixture before TFF; lane 3: IVT mixture after one wash volume (equal to the initial feed volume); lane 4: IVT mixture after TFF in nuclease-free water; lane 5: IVT mixture after TFF in nuclease-free water (after diafiltration with 2.5 M ammonium acetate and nuclease-free water, each mixture was concentrated 2.5-fold to efficiently detect protein removal). The enzyme mixture consisted of RNase inhibitor, T7 RNA polymerase, inorganic pyrophosphatase, and DNase I. [Figure 6]A) Western blot of hCFTR protein translated in HEK293 cells using Lipofectamine MessengerMax after transfection of hCFTR mRNA purified by TFF and hCFTR mRNA purified by precipitation with ammonium acetate followed by washing with 70% ethanol. Hsp90 protein bands are shown as housekeeping elements. Untransfected cells were used as negative control. B) Expressed hCFTR was quantified by densitometric analysis using Image Lab Software and normalized to HSP90 protein. Untransfected (UT) cells were used as negative control. [Figure 7] Figure 14. Amount of various non-hCFTR spike-in mRNA molecules remaining relative to the amount of hCFTR target mRNA molecules after different wash volumes in percentage. Tangential flow filtration was performed at RT. [Figure 8] Figure 14. Amount of various non-hCFTR spike-in mRNA molecules remaining relative to the amount of hCFTR target mRNA molecules after different wash volumes in percentage. Tangential flow filtration was performed at 4°C. [Figure 9] Capillary gel electrophoresis of tdTomato mRNA spiked with different DNA oligonucleotides (15 nt, 25 nt, and 120 nt), including a 25 nt antisense DNA oligonucleotide, was performed using a Fragment Analyzer before (A) and after (B) TFF purification at 4° C. The lower marker is an internal standard (a 15 nt long RNA oligonucleotide) provided in the Fragment Analyzer reagent kit to normalize the retention time of peaks in each capillary run. [Figure 10] Representatively, the permeation flux was measured at different transmembrane pressure set points. [Figure 11]Capillary gel electrophoresis of hCFTR mRNA spiked with DNA oligonucleotides of 25 nt and 120 nt in length, and GLP-1 mRNA molecules of 256 nt in length, before (A), after (Ib) (B), after (IIa) (C) and after (IIb) (D) purification by method 1 at RT, performed using a Fragment Analyzer. The lower limit marker is an internal standard (RNA oligonucleotide of 15 nt in length) provided in the Fragment Analyzer reagent kit to normalize the retention time of the peaks in each capillary run. [Figure 12] Capillary gel electrophoresis of hCFTR mRNA spiked with DNA oligonucleotides of 25 nt and 120 nt in length, and with GLP-1 mRNA molecules of 256 nt in length, was performed using a Fragment Analyzer before (A) and after (B) purification by method 2 at RT. The lower limit marker is an internal standard (RNA oligonucleotide of 15 nt in length) provided in the Fragment Analyzer reagent kit to normalize the retention time of the peaks in each capillary run.

[0123] Further aspects and advantages of the present invention are described in the following examples, which are intended for illustrative purposes. These are given by way of example and not by way of limitation. Each of the publications, patents, and patent applications cited herein are incorporated by reference in their entirety. EXAMPLES

[0124] Methods and materials are described herein for use in this disclosure; Other suitable methods and materials known in the art may also be used. The examples are illustrative only and are not intended to be limiting.

[0125] Abbreviations used herein and their associated definitions are listed in Table 3. do. [Table 3]

[0126] Materials and Methods Materials, equipment, software and test systems used The materials are listed in Table 4. [Table 4-1] [Table 4-2] [Table 4-3]

[0127] The equipment is listed in Table 5. [Table 5]

[0128] The software is listed in Table 6. [Table 6]

[0129] The test systems are listed in Table 7. [Table 7]

[0130] Purification of the IVT mixture by TFF - steps (Ia) and (Ib) In the following, the unmodified in vitro transcribed unmodified 1644 nucleotides (nt) in length Use an in vitro transcription (IVT) mixture containing tdTomato target mRNA molecules In addition, T7 RNA polymerase, inorganic pyrophosphatase, and RNase inhibitors were An enzyme mixture containing DNase I was used.

[0131] RNA precipitation The IVT mixture and the enzyme mixture were each diluted to a final concentration of 2.5 M NH4OAc. Precipitate with an equal volume of ice-cold 5M NH4OAc pH 7 and keep on ice until Both were incubated for 30 min. Before TFF, the final concentration in the mixture was approximately 0. Dilute each mixture with 2.5M NH4OAc pH 7 until the concentration is 5mg / ml mRNA. When the IVT or enzyme mixture was connected to the TFF system, the TF was first diluted 1:1. The F system was run with the IVT mixture circulating at 50 ml / min with the permeate clamp closed. The mixture was primed for 10 minutes by allowing the mixture to stand.

[0132] Step (Ia): Removal of proteins, nucleotides and salts Using an mPES filter column with a MWCO of 500 kDa, approximately 200-300 m Diafiltration of each mixture was performed at 50 ml / min at a constant TMP of 100 bar. Each mixture was diluted with 10 washes of 2.5M NH4OAc pH 7. This step allows the enzymes derived from in vitro transcription, nuclease Step (Ia) was used to efficiently remove the oxidants and buffer components. Intermediate production steps (e.g., dephosphorylation, postcapping, polyadenylation, ... Any other proteins and / or enzymes derived from the .) may be removed. (e.g., poly(A) polymerase that binds with high affinity to the mRNA molecule of interest) ), detergents (e.g. SDS, LDS, ...) are added to ammonium acetate buffer. - pH 7 may be added. Poly(A) polymerase is used for polyadenylation. If so, the subsequent step (Ia) is preferably carried out at a temperature between 20° C. and 30° C., preferably at 2 The reaction is carried out at a temperature of 3° C. to 27° C., more preferably at 25° C. Such a temperature is effective This is advantageous for removing poly(A) polymerase.

[0133] Step (Ib): Removal of NHOAc derived from step (Ia) The flow rate was 50 ml / min for the purpose of removing NH4OAc and splitting the mRNA molecules. 10 washes using nuclease-free water at 200-300 mbar TMP and For volumetric diafiltration, a 100 kDA MWCO mPES filter was used. Alternatively, a mPES filter column with a MWCO of 50 kDa was used. Depending on the size of the mRNA molecule, a variety of transcription factors may be used.

[0134] To investigate the purification efficiency of steps (Ia) and (Ib), TF containing mRNA molecules were The F retentate was sampled before and after TFF (i.e., step (Ib)) and, for example, V measurement, Fragment Analyzer, Sodium dodecyl sulfate-polyacrylic The protein was analyzed using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed by colloidal chromatography (e.g., colloidal chromatography). Massie staining can be applied.

[0135] As shown in Figures 3 to 5, the enzyme is subjected to the above steps (Ia) and (Ib). This allows the mRNA molecule to be efficiently removed from the Enzymes and / or proteins were efficiently removed while retained by the TFF column Smear peak analysis showed that the smear pre-peak was 4.7% before TFF purification. There was a deviation of +1.3% for TFF purification at 4°C and +1.3% for TFF purification performed at RT. After the addition of the 1.8% deviation, the mRNA degradation was found to be +1.8%. It was not possible to observe.

[0136] Purification of precipitated and dissolved mRNA by TFF - steps (IIa) and (IIb) Development of In the following, the precipitated and dissolved mRNA was used for further purification.

[0137] Examination of various filtration membranes and the effect of EDTA on mRNA permeation Various filter membranes with different pore sizes were used in nuclease-free water alone. If used, or nuclease-free water was added with an additional 10 mM ethylenediaminetetraacetic acid (E We tested the permeability of mRNA molecules when used together with DTA. Molecular weight cutoffs (MWC) of 500 kDa, 300 kDa, 100 kDa and 50 kDa Four mPES columns with 100% ethanol (100% ethanol) were tested. The transmembrane pressure (TMP) was measured using the TFF system. The retentate clamps were adjusted to MWCOs of 500 kDa and 50 kDa, respectively. The pressure in the column a was kept at 40 mbar, and the MWCOs were 100 kDa and 30 For the 0 kDa column, the pressure was kept at 100 mbar. The main pump was operated at 15 ml / min. The flow rate was set at 1000 s and TFF was performed at RT. Initial mRNA molecule concentration in the feed The concentration of mRNA molecules in the retentate and permeate was measured by UV measurement. Each column was washed with 10x the original sample volume. Tested.

[0138] In the absence of EDTA, mRNA molecules were loaded onto a test column with a MWCO of 500 kDa. The smaller pore sizes (i.e., 300 kDa, 100 kDa, and 50 It is assumed that the EDTA was not further tested in the absence of

[0139] Surprisingly, in the presence of EDTA, the mRNA molecule is bound to a 500 kDa MWCO fragment. The sample passes through the pores of the filter membrane and is then passed through a filter membrane with a MWCO of 300 kDa. However, the mRNA molecules were partially lost when 10 mM EDT was used. In the presence of A, filter membranes with MWCOs of 100 kDa and 50 kDa Therefore, in the experiments presented below, the MWCO A 100 kDa column was chosen for the filtration of mRNA molecules.

[0140] After filtration with 10 mM EDTA, sporadic precipitation of mRNA molecules was observed. However, it should be noted that there were also The above precipitation can be effectively prevented by using a buffer containing EDTA. Ta.

[0141] Preparation of 40 mM MOPS and 10 mM EDTA diafiltration buffer MOPS was dissolved in nuclease-free water and diluted to 1M 3-(N-morpholino)propanesulfonyl ether. A 1M monosulfonic acid (MOPS) buffer was then prepared using 32% NaOH. The pH of the MOPS buffer was adjusted to pH 7. The resulting 1M MOPS buffer at pH 7 The fur was mixed with 0.5M EDTA and nuclease-free water, ultimately resulting in a 40 The diafiltration buffer contained 10 mM MOPS and 10 mM EDTA. It was made.

[0142] Determining the volume of wash buffer to remove nucleic acid oligonucleotides The efficiency of the TFF process, i.e., abortive transcription products and / or hydrolysis products, The minimum number of wash cycles required for complete removal of impurities such as representative nucleic acid oligonucleotides The number of times is based on the strength of the membrane filter and the pore size of the membrane filter in excluding molecules. Therefore, the effect of each wash buffer volume was investigated to determine the Spiked nucleic acid oligonucleotides are extracted from precipitated and dissolved mRNA containing NA molecules. The number of wash cycles required for removal was determined.

[0143] For this experiment, an mPES filter column with a MWCO of 100 kDa was used. Above, the TFF flow rate was set to 15 ml / min and the TMP was kept constant at about 40 mbar. The total feed volume was kept at 5 ml, and 500 μL of mRNA molecules were added to the target mRNA. a DNA oligonucleotide of 10 nt in length corresponding to 2.5% (m / m) of the RNA molecule; A DNA oligonucleotide of 50 nt in length corresponding to 2.5% (m / m) of the target mRNA molecule nucleotide and 120 nt in length, corresponding to 5% (m / m) of the target mRNA molecule DNA oligonucleotides were spiked in 40 mM MOPS and 10 mM EDT. With diafiltration buffer containing A, the original feed volume After 5x, 10x, 15x and 20x washing volumes, samples were withdrawn for reversed-phase HPLC analysis. Before drawing the sample, the permeate clamp was closed and the retentate was allowed to circulate for 5 min. The retentate valve was opened for 5 minutes at 0 ml / min. During each wash cycle, a sterile Using a syringe, remove 100 μL samples and store these samples on ice until analysis. TFF was performed at room temperature. Samples were examined using reversed-phase HPLC analysis. However, the area detected at 260 nm was the area of ​​DNA oligonucleotides in the sample. The corresponding areas before TFF (control) were 100% oligonucleotides. It was set against leotide.

[0144] In all cases, 5x, 10x, 15x and 20x the feed volume, respectively After applying x washing volumes, no nucleic acid oligonucleotides could be detected. Therefore, this result shows that already after 5x washing volume with washing buffer, It was shown that the nucleic acid oligonucleotides could not be detected in the retentate. A minimum wash volume of 10x when using a buffer is required to separate the nucleic acid oligonucleotides from the mRNA molecules. It was determined that this was sufficient to remove the leotide.

[0145] Determining wash volume using nuclease-free water to remove EDTA The removal of DNA oligonucleotides by TFF was achieved by using a washing buffer, i.e., 40 A diafiltration buffer containing 10 mM MOPS and 10 mM EDTA was used. The subsequent filtration step is performed using nuclease-free wash buffers. Therefore, the experiment was carried out by exchanging the washing buffer with water from the mRNA molecules. This study was conducted to determine the amount of wash cycles required to remove the buffer. From the experiment, the diafiltration buffer was pre-filtered with 20x the wash volume. The feed solution containing the filtered mRNA molecules was mixed with a total volume of approximately 5 ml of a 100 kD MWCO A mPES filter column was used, with a flow rate of 15 ml / min and pressure of 40 mbar. At a constant TMP, it was diafiltered with nuclease-free water. 5x, 10x, 15x and 10x the original feed volume using nuclease-free water After 20x washing and 20x washing volumes, samples were taken for reversed-phase HPLC analysis. To quantify the amount of residual EDTA after each washing cycle with water, 40 mM MOP Diafiltration buffer containing S and 10 mM EDTA was titrated to obtain a calibration curve. was recorded (see Table 6; MOPS-EDTA calibration curve: log(y) = 0.6467 l og(x)+1.9128;r=0,99462;r 2 =0.99877;Curve model: The MOPS buffer alone did not show any absorbance signal at 260 nm. Therefore, the concentrations listed in Tables 8 and 9 correspond to the concentrations of EDTA. The experiments were performed at RT of 22°C. Table 9 shows the data after each wash cycle and after removing the EDTA. As shown.

[0146] As shown in Table 9, after increasing wash volumes, 260 nM of 100% was detected by reverse phase HPLC. The amount of EDTA decreased according to the peak area detected at 100 μm, resulting in the nuclease inhibition. A minimum of 10x wash volume using aqueous was used to partially remove residual EDTA. proved to be necessary. [Table 8] [Table 9]

[0147] Testing of measured parameters In the aforementioned experiments carried out at RT, the DNA oligonucleotide was Washing with diafiltration buffer required to remove nucleotides The minimum number of cycles and the number of cycles required to remove residual EDTA in step (IIb) The minimum number of wash cycles using nuclease-free water was determined. To test the target protein, 500 μg of mRNA was added to a total feed volume of 5 ml. a nucleic acid oligonucleotide of 10 nt in length corresponding to 2.5% of the volume of a single mRNA molecule; A DNA oligonucleotide of 50 nt in length, corresponding to 2.5% of the volume of the target mRNA molecule, and a 120-nt DNA fragment that corresponds to 5% of the volume of the target mRNA molecule. Oligonucleotides were spiked in (referred to as "Pre-TFF" in Tables 8 and 9). .

[0148] In the experiments described below, the following configuration was used unless otherwise stated: A mPES filter column with a WCO of 100 kDa was used at a flow rate of 15 ml / min. and a feed containing 0.1 mg / ml of mRNA molecules at a TMP of about 40 mbar. The solution was diafiltered. In each case, the wash volume applied was: 10x wash volume, i.e., dialysis with 40 mM MOPS and 10 mM EDTA. 10x wash volume with filtration buffer, followed by nuclease The wash volume was 10x that of the non-water wash (referred to as "Post-TFF" in Tables 8 and 9). Because mRNA molecules are susceptible to hydrolytic degradation, especially at high temperatures, the experiment was The procedure is carried out at 4 °C, i.e. using ice water, to keep hydrolysis of the RNA molecules to a minimum. It was carried out.

[0149] When measured using reverse phase HPLC, the above configuration produced 100% glycerol of all three lengths tested. DNA oligonucleotides (Table 10) and the remaining diafiltration buffer (Table 11) was efficiently removed. Furthermore, Fragment Analysis was performed before and after purification. Smear peak analysis was performed after capillary gel electrophoresis using r (Table 12). Smear peak analysis demonstrated that the integrity of the mRNA was not altered by TFF purification and therefore and was shown to be unaffected by the method. [Table 10] [Table 11] [Table 12]

[0150] Measuring the translation efficiency of purified mRNA molecules Furthermore, it would be of great interest to measure the translation efficiency of the resulting purified mRNA molecules. Therefore, 1.4 × 10 6 HEK293 cells were seeded in 6-well plates. 3.75 μg of mRNA molecules purified as above and purified by standard procedures The cells were transfected with 3.75 μg of the mRNA molecule. The cross-section was performed using MessengerMax (1:15). After 24 hours, After lysing the cells, five samples were analyzed using SDS-Page and Western blot, respectively. 0 μg of each cell lysate was used.

[0151] As can be seen in Figure 6, Western blot (A) revealed comparable amounts of mRNA. The offspring were detected and quantified (B).

[0152] Determining the threshold for removing different length mRNAs A total of 300 μg of mRNA targeting hCFTR mRNA was used in a total volume of 5 ml. The 6 mRNAs were spiked into the cells with different lengths of mRNA molecules. molecules were used for spiking, each type being 16. The three mRNA molecules exhibited a cap and a poly(A) tail. The total lengths of the two genes were 3,632nt, 1,864nt, and 1,111nt, respectively. The mRNA molecule has neither a cap nor a poly(A) tail, and is 494 nt and 256 nt long, respectively. The total length in nt is shown. The last type of mRNA molecule serves as a positive control. The DNA length was assigned to an oligonucleotide of 120 nt.

[0153] Solutions containing spiked mRNA molecules were incubated at RT (Figure 7) and 4°C ( Before TFF (immediately after sample preparation), the samples were filtered through the diafiltration filter described above. 5x, 10x, 15x and 2x the original sample volume using lysis buffer After 0x wash volume and after a further wash with 10x wash volume of nuclease-free water Samples were drawn using a sterile syringe for 100 min at each wash cycle. A 1 μl sample was withdrawn and kept on ice until analysis. The permeation of the protein was analyzed by capillary gel electrophoresis using a Fragment Analyzer. Therefore, it was evaluated.

[0154] As shown in Figures 7 and 8, the cut mRNA molecule having a length of 951 nt Off-regulation could be observed using a 100 kDa mPES column. For mRNA molecules of length 10 kDa, for example, 50 kDa or 70 kDa mPES columns are used. In some cases, a column with a lower MWCO, such as a column with a 100% MWCO, may be advantageous.

[0155] Increasing the concentration of mRNA molecules from 0.1mg / ml to 1mg / ml In the final set of experiments below (Figure 9), the filtration procedure described below was performed on the target mRNA A solution containing unmodified tdTomato mRNA of length 1644 nt as molecule A In particular, a concentration of 1 mg / ml of mRNA molecules was used, which corresponds to a total of 5 mg of mRNA molecules. and a 15-nt DNA oligonucleotide corresponding to 2.5% (m / m) of the target mRNA molecule. nucleotide and antisense oligonucleotide of 25 nt in length (targeting the mRNA molecule of interest) (complementary to the target mRNA) and a 12-kDa fragment of length 5% (m / m) of the target mRNA molecule. A total of 5 ml of feed solution containing 0 nt oligonucleotide was analyzed. The purified feed solution was filtered using a 100 kDa MWCO mPES filter column. The diafiltration was performed at 4°C with a flow rate of 15 ml / min and a TMP of approximately 40 mbar. The wash volumes applied were: i) 10x wash with nuclease-free water; followed by ii) dialysis with 40 mM MOPS and 10 mM EDTA. 10x wash volume with filtration buffer, followed by iii) nuclear The wash volume was 10x that of enzyme-free water.

[0156] As an indicator of mRNA integrity, the smear values ​​were investigated. In particular, the following smear values ​​were obtained: : 6.4% smear pre-peak before TFF and 5.9% smear pre-peak after TFF The pre-smear peak area reflects the ratio of hydrolysis products related to mRNA. Therefore, the hydrolysis products were measured by Fragment Analyzer. We could not determine whether TFF purification affects the integrity of the mRNA. Ta.

[0157] Exemplary Overview of Determining Optimal TFF Parameters Using Conventional Means The following describes how one skilled in the art can optimize the above TFF method by applying routine procedures. This is a simple explanation of how this can be done.

[0158] Step (Ia) The TFF flow rate recirculates the precipitated mRNA molecules within the TFF system and Adjust the shear rate to provide a rate sufficient to sweep precipitated mRNA molecules away from the surface. By opening the permeate clamp, sufficient permeate flux can be obtained. The removal of the enzyme can be measured, for example, by SDS-Page analysis and the required washes. The amount can be adjusted by conventional means (preferably 1 to 20 times the amount of washing; (Preferably 5-15 times; most preferably 9-11 times). The washing volume is 1:1 relative to the initial feed volume. of an equal diafiltration medium, e.g., ammonium acetate buffer at pH 7. It is defined as a volume.

[0159] Step (Ib) The same parameters as described in step (Ia) were applied, whereby the buffer For example, degrades mRNA molecules and removes buffers (e.g., ammonium acetate) To avoid this, the buffer can be exchanged with nuclease-free water. , conductivity, UV measurements and the amount of cleaning required can be determined by conventional means. The amount of washing can be adjusted (preferably 1 to 20 times; more preferably 5 to 15 times; maximum The washing volume is preferably 9 to 11 times the initial feed volume of the diafiltration tray. The volume of the purification medium, e.g., nuclease-free water, is defined as the volume of the purification medium.

[0160] Step (IIa) The TFF flow rate recirculates the mRNA molecules within the TFF system and separates them from the filter surface. The shear rate can be adjusted to provide sufficient shear to sweep the RNA molecules through. By opening the permeation clamp, sufficient permeation flux can be obtained. The loss of A can be determined, for example, by UV measurement in the permeate line (e.g., online / offline Loss of the mRNA of interest can be monitored by measuring its expression. When the flow rate and / or TMP are adjusted such that no further loss of the mRNA of interest is observed, The amount of washing required can be adjusted by conventional means to the amount of impurities (e.g., The amount of the votive transcript and / or hydrolysis product is adjusted by conventional means. (preferably 1 to 20 times the washing amount; more preferably 5 to 15 times; most preferably (Or 9-11 times). The wash volume is the diafiltration volume equal to the initial feed volume. It is defined as the volume of vehicle, for example MOPS-EDTA at pH 7.

[0161] Step (IIb) The same parameters as described in step (IIa) were applied, whereby the buffer For example, to remove buffers such as MOPS-EDTA, nuclease-free The buffer can be exchanged by adding water. Removal of the buffer can be confirmed by, for example, conductivity or UV measurement. and the amount of washing required can be adjusted by conventional means ( Preferably 1 to 20 times the washing amount; more preferably 5 to 15 times; most preferably 9 to 11 times 1 The wash volume is a volume of diafiltration media, e.g., Nu It is defined as the volume of creatine-free water.

[0162] The TMP excursion experiment was carried out using mRNA This can help determine optimal conditions for purifying the molecule. 1.0 mg / ml in the diafiltration buffer used in A total of 5 ml of feed solution containing the target mRNA molecules at a concentration of 100k Diafiltration was performed using a 15 Da mPES filter column and a flow rate of 15 ml / min. The permeation flux was measured at six different T values ​​ranging from about 50 mbar to about 150 mbar. MP values ​​were measured in ml / min. As can be seen from the RNA, the optimal TMP is approximately 50mb at a flow rate of 15ml / min. It was determined that the TMP was ar, but this optimal TMP may depend on the experimental setup.

[0163] Comparative Example The following are the results obtained by the method disclosed in this specification (Method 1) and the results of the method disclosed in WO2015 / This was carried out to compare the results obtained by the method (Method 2) disclosed in 164773A1. An example is given.

[0164] Method 1 In vitro transcribed unmodified hCFTR mRNA (see US9713626B2; 5mg The pellets were then filled with DNA oligonucleotides of 25 nucleotides (nt) and 120 nt in length. leotide, and one molecule of glucagon-like peptide (GLP-1 mRNA) of 256 nt in length. The molecule (SEQ ID NO: 1) was spiked with a DNA oligonucleotide of 25 nt in length. Spike into mRNA at a ratio of 2.5% of the total amount of mRNA in grams. A DNA oligonucleotide of 120 nt in length was added to the total amount of mRNA in μg. In addition, a 256-nt long G LP-1 mRNA molecules were diluted to a ratio of 16% of the total amount of mRNA in μg. spiked into sea urchin mRNA. Precipitate the spiked mRNA molecules using 2.5M NH4OAc (pH 7). I did. A flow rate of 50 mL / min to remove proteins, salts, and abortive transcription products and MWCO at approximately 200-300 mbar TMP (mRNA concentration: 0.5 mg / mL). 10x wash volume of 2.5M NH4OAc using 500kDa mPES Step (Ia) was carried out. A flow rate of 50 mL / min was used to remove NH4OAc and degrade the mRNA molecules. Using mPES with a MWCO of 50 kDa at a TMP of approximately 200-300 mbar, Step (Ib) was performed with x wash volumes of nuclease-free water (mRNA concentration: 0 .5mg / mL). To remove divalent cations, abortive transcription products, and / or hydrolysis products, mPE with MWCO of 100 kDa at a flow rate of 15 mL / min and a TMP of approximately 20 mbar Use 10x wash volumes of 40 mM MOPS and 10 mM EDTA to stain the stems. A loop (IIa) was performed (mRNA concentration: 1.0 mg / mL). To remove the MOPS-EDTA diafiltration buffer, 15 mL mPES with MWCO of 100 kDa was used at a flow rate of 1 / min and a TMP of approximately 20 mbar. Step (IIb) was then carried out using 10x wash volume of nuclease-free water (mR NA concentration: 1.0 mg / mL). The resulting mRNA molecules were purified using the Fl The recovery of mRNA molecules was investigated using an Aggregation Analyzer / Reversed Phase HPLC. The measurements were carried out using a Nanodrop.

[0165] Method 2 (described in WO2015 / 164773A1) In vitro transcribed unmodified hCFTR mRNA (see US9713626B2; 10. The 26 mg pellet contained DNA fragments of 25 nucleotides (nt) and 120 nt in length. oligonucleotide, as well as the GLP-1 mRNA molecule of 256 nt in length (SEQ ID NO:1). A DNA oligonucleotide of 25 nt in length was spiked into the mRNA in μg. A was spiked into mRNA at a ratio of 2.5% relative to the total amount of A. DNA oligonucleotides were added at a ratio of 5.0% to the total amount of mRNA in μg. In addition, the 256-nt GLP-1 mRNA fragment was spiked into the mRNA. The oligonucleotide was spiked into mRNA at a ratio of 16% of the total amount of mRNA in μg. I did. The spiked mRNA molecules were incubated with: i) 2.09 M guanidinium thiocyanate; 0.26% sodium lauryl sarcosyl yl) and guanidinium citrate to a final concentration of 13.0 mM sodium citrate. ocyanate, sodium lauryl sarkosyl and sodium citrate, and ii) Precipitate using absolute ethanol to a final concentration of approximately 38% EtOH and store at RT. Incubated for 5 minutes. Approximately 22 mL of mPES with a MWCO of 500 kDa was used at a flow rate of approximately 6 mL / min. Loading was performed using precipitated mRNA (mRNA concentration: 0.52 mg / mL ). Using mPES with a MWCO of 500 kDa at a flow rate of approximately 6 mL / min, Washing was performed by repeating the step five more times (mRNA concentration: 0.52 Step a) Add 5 mL of 2.09 M guanidinium thiocyanate and 0 26% sodium lauryl sarkosyl, 13.0 mM sodium citrate, and about 3 Step b) washing with 5 mL of 8% EtOH and step c) washing with 5 mL of 80% ethanol Use to clean. The solid-state mRNA obtained was treated with 5 mL of nuclease-free water for 5 to 10 minutes (permeation The elution (step C) is completed by recirculating the solution (closed) to ensure complete dissolution. The flow rate and MWCO were adjusted to approximately 6 mL / min until no mRNA molecules were recovered. This procedure was repeated using mPES with a molecular weight of 500 kDa (mRNA concentration: 0.52 mM g / mL). Approximately 5 wash volumes with 1 mM sodium citrate (pH 6.4), approximately 6 mL / min mPES with a flow rate of 100 kDa and MWCO of 100 kDa (mRNA concentration: 0.52 mg / mL) Dialysis (step D) was carried out using The resulting mRNA molecules were purified using the Fla The recovery of mRNA molecules was measured using a HPLC / Gene Analyzer. The determination was investigated using Nanodrop.

[0166] It should be noted that the above two methods are more effective than the method described in WO2015 / 164773A1. The following changes were made: Linearization to keep the shear rate constant in the filter column. After downscaling the shape, the flow rate was initially planned to be 6 mL / min. However, this flow rate results in a very low TMP, i.e., an effective permeate flow rate. The flow rate was 0 mL / min, and diafiltration was not possible. The flow rate is increased stepwise until a sufficient TMP is observed to result in a reasonable permeation flux. Therefore, the final flow rate used for steps a) to d) is 20 to 24 m L / min (permeate flow rate of 1.1-1.25 mL / min).

[0167] Unpurified and purified hCFTR mRNA samples The Fragment Analyzer analysis performed on the The results were as shown in FIG. 11 for Method 1. Method 2 is shown in FIG. [Table 13]

[0168] For method 1, spiked DNA oligonucleotides (25 nt and 120 nt) The removal of was achieved mainly by steps (Ia) / (Ib). Step (IIa) is required to remove the 256-nt mRNA, which corresponds to the longer hydrolysis product. Step (IIb) does not further remove the 256 nt mRNA, which To remove water decomposition products and abortive sequences It has been shown that step (IIa) using a strong chelating agent such as EDTA is essential for was shown.

[0169] For method 2, spiked DNA oligonucleotides (25nt and 120nt) The removal of 120n was only partially achieved by steps A to C. Step D was The DNA oligonucleotides of the t were not completely removed. The corresponding 256-nt mRNA remained almost completely in the samples after TFF purification. Therefore, dialysis is performed using 1 mM sodium citrate (step D). This means that the 120 nt long DNA oligonucleotide, which corresponds to the failed mRNA molecule, In particular, it was strong in further removing the 256 nt mRNA, which corresponds to the longer hydrolysis product. had no significant impact.

[0170] Below, the 256 nt long mRNA sequence used herein is described in more detail. It is described in. SEQ ID NO:1 Codon-optimized GLP-1 sequence GGGAGA CUGCCAAGAUGAAGAUCAUCCUGUGGCUGUGCGU GUUCGGCCUGUUCCUGGCCACCCUGUUCCCCAUCAGCUGG CAGAUGCCUGUGGAAAGCGGCCUGAGCAGCGAGGAUAGCG CCAGCAGCGAGAGCUUCGCCAAGCGGAUCAAGAGACACGG CGAGGGCACCUUCACCAGCGACGUGUCCAGCUACCUGGAA GGCCAGGCCGCCAAAGAGUUUAUCGCCUGGCUCGUGAAGG GCAGAGGCUGA GAAUU T7プロモーターの部分 C: Ethris minimal 5'UTR, followed by U nucleotides, TISU 5'UTR, start codon, codon-optimized GLP -1 mRNA sequence, stop codon, EcoRI制限部位の部分 Non-polyadenylated mRNA was used for spiking experiments.

Claims

1. (Ia) A first solution is used to separate precipitated mRNA molecules from a suspension containing precipitated mRNA molecules. purifying the RNA molecule; (Ib) using the second solution to purify the purified precipitate obtained in step (Ia) washing and solubilizing the isolated mRNA molecules; (IIa) The third solution containing a chelating agent is used to purify the chelating agent obtained in step (Ib). purifying the mRNA molecules from the collected dissolved mRNA molecules, followed by (IIb) using the fourth solution, washing the mRNA molecules; A method for purifying an mRNA molecule, comprising the steps of: The method is carried out using gentle flow filtration.

2. The method of claim 1 , wherein the chelating agent is EDTA.

3. The method of claim 1 or 2, wherein the third solution has a pH of from 1 to 10.

4. 4. The method according to claim 1, wherein the third solution comprises a MOPS buffer. Method of posting.

5. 5. The process according to claim 1, wherein steps (Ia) to (IIb) are carried out at a temperature between 0° C. and 25° C.

2. The method according to claim 1 .

6. Prior to step (Ia), the suspension is treated with ammonium acetate to precipitate the mRNA molecules.

6. The method according to claim 1, wherein the first solution contains ammonium acetate.

2. The method according to claim 1 .

7. The second solution is water and / or the fourth solution is water or sodium chloride.

7. The composition according to claim 1 , further comprising sodium citrate and / or sodium citrate. method.

8. 8. The method according to claim 1, wherein the mRNA molecule is contained in the retentate after tangential flow filtration. The method according to any one of claims 1 to 5.

9. The retentate obtained in step (Ia) is subjected to tangent separation in step (Ib). The solution obtained in step (Ib) was used as the feed solution for the step-flow filtration. The retentate is used as a feed solution in step (IIa), and The retentate obtained in step (a) is used as a feed solution in step (IIb). The method of claim 8 .

10. 10. The method according to claim 1, wherein the mRNA molecules contained in the suspension are obtained by in vitro transcription.

2. The method according to claim 1 .

11. Dephosphorylate and / or polyadenylate and / or post-cap the mRNA molecule. The method of claim 1 , further comprising:

12. Dephosphorylating the mRNA molecules obtained in step (Ib) and subsequently The steps (Ia) to (IIb) are carried out, and the resulting mRNA molecule is then subjected to polyamine synthesis. and subsequently carrying out steps (Ia) to (IIb). The method of claim 11.

13. In the case of step (Ia), the molecular weight cut-off is between 300 kDa and 0.65 μm. The filter membrane is used for tangential flow filtration and / or step In the case of groups (Ib) and (IIb), the molecular weight cutoff is between 1 kDa and 0.65 μm. In the case of step (IIa), a filter membrane is used, and / or at least In both cases, a filter membrane with a molecular weight cutoff of 70 kDa is used. Item 13. The method according to any one of items 1 to 12.

14. the amount of diafiltration of any of the first, second, third and / or fourth solutions is 14. Any of claims 1 to 13, wherein the volume of the suspension of step (Ia) is at least 1-fold. The method according to any one of claims 1 to 5.

15. (a) purifying an mRNA molecule by the method according to any one of claims 1 to 14; And, (b) incorporating the mRNA molecule thus obtained into a pharmaceutical composition. A method for producing a pharmaceutical composition comprising:

Citation Information

Patent Citations

  • METHOD FOR EFFECTIVELY QUANTIFYING SPECIFIC mRNA COMPRISING SPECIFIC SEQUENCE FROM SAMPLE

    JP2010162050A

  • Method for analyzing target nucleic acid

    JP2012125200A

  • How to purify messenger RNA

    JP2017518734A

  • mRNA purification by tangential flow filtration

    JP2022521161A

  • mRNA purification by tangential flow filtration

    JP7610845B2